

Media coverage of CANMAb™ launch announcement, Jan 18, 2014:

TV Channel:

Subject	Biocon Launches Cancer Drug - CANMAb
Channel	ET Now
Program	Morning Mantra
Date	Monday, January 20, 2014
Telecast Time	07:26am
Duration	02min 09sec
External Link	http://www.biocon.com/channelinterview/200114/ETNow_0726am_Jan20.wmv

Subject	Biocon Launches Cancer Drug - CANMAb
Channel	Bloomberg TV
Program	First Trades
Date	Monday, January 20, 2014
Telecast Time	08:26am
Duration	03min 01sec
External Link	http://www.biocon.com/channelinterview/200114/BloombergTV_0826am_Jan20.wmv

Print Coverage:

Sl. No.	Publication	Edition	Headline
1	Economic Times	Bangalore/Delhi/Kolkata	Biocon launches breast-cancer drug
2	Economic Times	Mumbai/Delhi	Biocon to Start Selling Cancer Biosimilar CANMAb at INR19,500
3	Business Line	Bangalore/Delhi/Mumbai/Kolkata	Biocon's cheaper cancer biosimilar drug to hit market in Feb
4	Business Line	Mumbai	Cheap drug to boost Biocon
5	Business Standard	Bangalore/Delhi/Mumbai/Chennai/Kolkata	Biocon launches first breast cancer biosimilar World's 1st biosimilar drug for breast cancer
6	Financial Express	Bangalore/Delhi/Kolkata	Biocon launches drug for breast cancer with aggressive pricing
7	Financial Express	Mumbai	Biocon launches drug for breast cancer, prices it aggressively
8	Times of India	Bangalore	Biocon launches new breast cancer drug
9	Times of India	Mumbai	Biocon's breast cancer drug to hit market in Feb
10	Financial Chronicle	Bangalore/Delhi/Mumbai/Chennai	Biocon launches breast cancer drug in Indian
11	The Hindu	Bangalore/Kolkata/Delhi	Biocon launches cheaper breast cancer drug
12	The Hindu	Mumbai	Cheap drug to boost Biocon
13	Deccan Herald	Bangalore	Biocon's cancer drug not affordable: Activist
14	Deccan Herald	Delhi	Biocon's CANMAb to hit markets
15	Deccan Chronicle	Bangalore	Biocon launches biosimilar drug to treat breast cancer

16	Indian Express	Bangalore/Delhi/Mumbai/ Chennai/Kolkata	Biocon's New Breast Cancer Drug CANMAb to Hit Markets next month
17	Trinity Mirror	Chennai	Biocon launches new breast cancer drug
18	National Standard	Bangalore	Biocon's breast cancer drug to hit market next month
19	Vijaya Vani	Bangalore	Kannada: Bio Medicine for Breast Cancer
20	Udayavani	Bangalore	Kannada: Cheap medicine for Breast Cancer
21	Kannada Prabha	Bangalore	Kannada: CANMAb for Breast Cancer
22	Dinakaran	Bangalore	Tamil: Biocon launches new breast cancer drug
23	Eenadu	Bangalore	Telugu: Biocon launches new breast cancer drug
24	Sakshi	Bangalore	Telugu: Biocon launches new breast cancer drug
26	Morning News	Jaipur	Hindi: Biocon launches new breast cancer drug
27	Dainik Bhaskar	Bangalore	Hindi: Biocon launches new breast cancer drug
28	Dinamai	Bangalore	Tamil: Biocon launches new breast cancer drug
29	Economic Times	Delhi	Hindi: Biocon launches new breast cancer drug
30	Dainik Tribune	Delhi	Hindi: Biocon launches new breast cancer drug
31	Anand Bazaar Patrika	Kolkata	Bengali: Biocon launches new breast cancer drug
32	Dainik Viswamitra	Kolkata	Bengali: Biocon launches new breast cancer drug

Online Coverage:

Sl. No.	Publication	Type	Headline
1	Economic Times	Online	Biocon's breast cancer drug 'CANMAb' to hit markets next month
2	Economic Times	Online	Biocon launches breast-cancer drug CANMAb
3	Times of India	Online	Biocon-Mylan develop biosimilar to treat cancer
4	The Hindu	Online	Biocon launches cheaper breast cancer drug
5	Money Control	Online	Biocon to start selling breast cancer drug in India in Feb
6	Mint	Online	Biocon's breast cancer drug CANMAb to hit markets in February
7	Business Standard	Online	World's 1st biosimilar drug for breast cancer
8	Business Standard	Online	Biocon to start selling breast cancer drug in India in February
9	Business Line	Online	Biocon's cheaper cancer biosimilar drug to hit market in Feb
10	Business Line	Online	Cheap drug to boost for Biocon
11	First Post	Online	Biocon launches world's first biosimilar drug for breast cancer
12	Reuters	Online	Biocon to start selling breast cancer drug in India in February
13	Myiris	Online	Biocon introduces CANMAb for treating breast cancer in India
14	New Indian Express	Online	Biocon's New Breast Cancer Drug CANMAb to Hit Markets Next Month
15	Equity Bull	Online	Biocon Launches a Biosimilar Trastuzumab for Treating Breast Cancer in India
16	Deccan Herald	Online	Biocon's cancer drug not affordable: Activists
17	PharmaExpress	Online	Biocon introduces CANMAb for treating breast cancer in India
18	NDTV Profit	Online	Biocon to start selling breast cancer treatment drug in India in February
19	Net India	Online	Biocon introduces biosimilar for treating breast cancer in India
20	Health	Online	Biocon's affordable breast cancer drug CANMAb launched
21	DNA	Online	Biocon releases drug to treat breast cancer
22	Biotechnika	Online	"CANMAbTM" - World's First Biosimilar Trastuzumab for Treating Breast Cancer Launched By Biocon in India
23	APN News	Online	Biocon introduces CANMAb for patients in India
24	BioSpectrum	Online	Biocon launches world's first Biosimilar 'CANMAb' in India
25	First World Pharma	Online	Biocon launches first biosimilar version of Roche's breast cancer drug Herceptin
26	bjb transfer valas	Online	Biocon akan Jual Obat Kanker Payudara di India
27	WebIndia123	Online	Biocon introduces CANMAb biosimilar for treating Breast Cancer
28	MoneyLife	Online	Biocon Introduces CANMAbTM - World's First Biosimilar Trastuzumab for Treating Breast Cancer in India
29	Navbharat	Online	Biocon introduces CANMAb biosimilar for treating Breast Cancer

Print Clips

Publication: Economic Times

Date: Jan 19, 2014

Edition: Bangalore/Delhi/Kolkata

Biocon launches breast-cancer drug

Mumbai: Bangalore-based drugmaker Biocon on Saturday launched CANMab, the biosimilar version of anti-cancer drug Herceptin, a move that analysts say would be a high revenue generator for the company. Biocon which developed the drug in association with US drugmaker Mylan received the approval last year. Originally developed by Swiss drugmaker Roche the drug is believed to be one of the most effective medicines in targeting the HER 2 cancer cell, which leads to breast cancer. Priced at ₹19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.

"The launch of CANMab in India is an important milestone for our bio-

similar programme and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product," said Kiran Mazumdar Shaw in a press statement.

Biocon said the drug will be manufactured at the company's Bangalore facility and will be available to patients around the first week of February 2014. CANMab will be available at about 25% discount to the current list price of the reference product in India, which is already signifi-

cantly lower than its price in developed markets, according to the company.

In August last year Roche decided not to pursue the Herceptin patent in India and paved the way for other generic makers to manufacture the drug. Since the science involved in producing the drug is complex, there are no other players apart from Biocon and Roche which manufacture this drug in India. The other company which is researching on generic Herceptin is Mumbai-based BDR Pharma.

— Our Bureau



Kiran Mazumdar Shaw

Publication: Economic Times

Date: Jan 20, 2014

Edition: Mumbai/Delhi

In a Nutshell

■ Biocon to Start Selling Cancer Biosimilar CANMab at ₹19,500

MUMBAI Bangalore-based biotechnology major Biocon said it will start selling CANMab, the biosimilar version of Swiss drug maker Roche's anti-breast cancer drug Herceptin, in the country from next month. The drug, developed in association with US-based Mylan, had received the Indian drug regulator's approval last year. Biocon has priced the drug at ₹19,500 per vial, which is a significant discount to Herceptin that is sold at ₹75,000.

Biocon's cheaper cancer biosimilar drug to hit market in Feb

Our Bureau

Bangalore, Jan. 18

Biotech major Biocon has launched CANMab (biosimilar Trastuzumab) for treating breast cancer in the Indian market from next month.

The company has priced the drug 25 per cent lower than the market leader Herceptin, which is sold by Roche.

CANMab has been developed jointly by Biocon and the US-based Mylan and made available in 150 mg/440 mg.

The company has priced it at Rs 19,500 per vial for 150 mg and Rs 57,500 for 440 mg.

"Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMab will offer a high quality, more affordable option to breast cancer patients in India," said Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, after launching the drug.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab, which offers the same level of safety and efficacy as the reference product (Herceptin)," she added. Talking about the opportunity for biosimilar Trastuzumab, Kiran Mazumdar-Shaw, said: "The global sales for Herceptin stood at over \$6.4 billion in 2012, while in India it recorded sales of over \$21 million."



Kiran Mazumdar-Shaw, Chairperson and MD, Biocon, at the launch of CANMab in Bangalore on Saturday.

— G.R.N. Somashekar

"The Biocon-Mylan joint development programmes are on target.

"The two companies are

working on eight molecules at present in the auto-immune and oncology space.

"Few molecules are in global clinical development, which is under way at multiple sites across the globe," said Abhijit Bharve, President R&D, Biocon.

The company's branded formulations business CAGR is 30 per cent.

amil.u@thehindu.co.in

Publication: Business Line

Date: Jan 20, 2014

Edition: Mumbai

Cheap drug to boost Biocon

Shares of Biocon will hog the limelight this week as the company launched a new and cheaper drug to treat 'metastatic' breast cancer that aggressively spreads to other parts of the body. The company said its product would cost about 25 per cent less than the original. Roche sells the drug in India as Herceptin, which generated in 2012. Sales worth around Rs 130 crore. Globally, it was around \$6.4 billion. Biocon's tumour-targeting product is slated to enter the market in the first week of February. It will make breast cancer treatment more affordable and accessible to many Indian patients who test positive for the cancer-indicating HER2 (short for human epidermal growth factor).



Publication: Business Standard

Date: Jan 19, 2014

Edition: Bangalore/Delhi/Mumbai/Chennai/Kolkata

COMPANIES, P4

Biocon launches first breast cancer biosimilar

Bangalore-based Biocon, a global biopharmaceutical company, on Saturday launched the world's first biosimilar (developed in an organism) Trastuzumab injection for the treatment of breast cancer. This is the first drug developed by Biocon in partnership with US-based generic drug maker Mylan. The new drug, CANMab, will be used to treat HER2-positive advanced breast cancer.

Biocon CMD Kiran Mazumdar-Shaw said the company would also launch the injection in other emerging markets.

World's 1st biosimilar drug for breast cancer

Biocon with Mylan eyes emerging markets for first joint drug

BS REPORTER
Bangalore, 18 January

Bangalore-based bio-pharmaceutical company Biocon on Saturday launched the world's first biosimilar (developed in an organism) Trastuzumab injection for the treatment of breast cancer here. This is the first drug developed by Biocon in partnership with US-based generic drug maker Mylan. The new drug, CANMab, will be used to treat HER2-positive advanced breast cancer.

Kiran Mazumdar-Shaw, chairperson and managing director, Biocon, said the company would also launch the injection in other emerging markets. The CANMab injection will compete with Roche's Herceptin. Herceptin's global sales were \$6.4 billion in 2012 and Indian \$21 million.

The drug has been jointly developed out of five molecules with Mylan, since a partnership was signed in 2009. Mylan will also launch CANMab under a different brand in India.

The injection is available in 150mg and 440mg doses at ₹19,500 and ₹57,500, respectively. The 440mg dose costs a fourth less than competing drugs, Mazumdar-Shaw said.

Biocon has set up a factory in Bangalore to make the new



JOINT EFFORT

- CANMab, developed jointly by Biocon & Mylan, to treat advanced breast cancer
- Competing drug Roche's Herceptin (pictured) global sales \$6.4 billion in 2012 and Indian \$21 million
- Mylan to launch CANMab under a different brand in India
- The injection in 150mg and 440mg doses to come for ₹19,500 and ₹57,500, respectively
- Biocon's factory in Bangalore to make the new injection for itself as well as Mylan

injection for itself as well as Mylan. Mylan will source its requirements from Biocon for both Indian and developed markets, a senior company official said. Biocon entered into partnership with Mylan for joint development of a series of drugs for the treatment of various cancers in 2009. At present, four other drugs are under development, of which will begin clinical trials later this year, said

Abhijit Barve, president (research and development), Biocon. Mazumdar-Shaw said breast cancer was the most prevalent cancer among Indians and CANMab would offer a cheaper option. About 150,000 new patients are diagnosed with breast cancer every year in India, of which nearly a fourth of the cases are HER2-positive and eligible for treatment with CANMab. Lack of cheap treatment has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher, she said.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab, which offers the same level of safety and efficacy as the reference product. The launch of CANMab in India is an important milestone for our biosimilars programme and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product," the Biocon chief said.

Biocon aims to capture about 15 per cent of the market for anti-breast cancer drugs in India in a year. The market is estimated at ₹130 crore a year, set to double in 2014.

Biocon launches drug for breast cancer with aggressive pricing

fe Bureau

Bangalore, Jan 18: Biocon, the country's largest biotechnology company, on Saturday launched its drug for breast cancer, CANMab, targeting the ₹130-crore Indian market.

The drug is the world's first biosimilar of Swiss drugmaker Roche's Herceptin.

Biocon said that CANMab, to be sold in vials, will be available in the Indian market in February while phase-3 trials for overseas markets like Europe and the US are in progress.

The Bangalore-headquartered company has developed the drug jointly with American pharma company Mylan under a global partnership.

Biocon has priced the drug nearly 25% lower than Herceptin apart from introducing smaller vials aimed at making treatment more affordable.

While Herceptin is priced at ₹75,000 per 440-mg vial, CANMab will be sold for ₹57,500 per 440-mg vial.

The smaller 150-mg vial will be available for ₹19,500. With this pricing, the company expects to win patients who couldn't previously afford treatment.

Global sales for Herceptin were around \$6.4 billion in 2012 while its India sales were estimated at \$21 million. The market for breast cancer drugs in India is expected to double in a couple of years.

Breast cancer is the most common form of cancer among Indian women, with an estimated 1.5 lakh new patients diagnosed every year in India. Of these, nearly 25% cases are HER2-positive.

Biocon said that CANMab is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells.

The drug is to be administered intravenously, once every three weeks or on a weekly basis, depending on the patient's condition, it said.

"Breast cancer survival rate has improved to 90% after the introduction of bio-



CANMAB WILL BE SOLD FOR ₹57,500 PER 440-MG VIAL. THE SMALLER 150-MG VIAL WILL BE AVAILABLE FOR ₹19,500. WITH THIS PRICING, THE COMPANY EXPECTS TO WIN PATIENTS WHO COULDN'T PREVIOUSLY AFFORD TREATMENT. THE MARKET FOR BREAST CANCER DRUGS IN INDIA IS EXPECTED TO DOUBLE IN A COUPLE OF YEARS

logics," said Kiran Mazumdar-Shaw, chairperson and managing director, Biocon.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab, which offers the same level of safety and efficacy as the reference product."

She added that the launch in India was a key milestone for the company's biosimilars programme. The drug will be manufactured at Biocon's Bangalore facility.

Publication: Financial Express

Date: Jan 19, 2014

Edition: Mumbai

Biocon launches drug for breast cancer, prices it aggressively

By Bureau

Bangalore, Jan 18: Biocon, India's largest biotechnology company, on Saturday launched its drug for breast

cancer, CANMab, targeting the ₹130-crore Indian market.

The drug is the world's first biosimilar of Swiss drugmaker Roche's Herceptin.

Biocon said that CANMab,

to be sold in vials, will be available in the Indian market in February while phase-3 trials for overseas markets like Europe and the US are in progress. The Bangalore-

headquartered company has developed the drug jointly with American pharma company Mylan under a global partnership. Biocon has priced the drug nearly 25%

lower than Herceptin apart from introducing smaller vials aimed at making treatment more affordable.

While Herceptin is priced at ₹75,000 per 440 mg vial, CAN-

Mab will be sold in 440-mg vial. The 150-mg vial will be priced at ₹19,500. The company aims to win patients who cannot afford treatment.

Publication: Times of India

Date: Jan 19, 2014

Edition: Bangalore

Biocon launches new breast cancer drug

TIMES NEWS NETWORK

Bangalore: Biopharmaceutical major Biocon recently launched a new injectable drug for treatment of a highly prevalent form of breast cancer. The product price is 25% lower than existing drugs in the market.

After cervical cancer, breast cancer is the most common form of cancer among Indian women, with 1.5 lakh new patients being diagnosed with the condition every year. Of that, nearly 25% are diagnosed with a particular type of breast cancer known as HER2-positive breast cancer. Biocon's new drug, called CANMAB, priced at Rs 57,500 for a 440mg vial and Rs 19,500 for a 150mg vial, has been developed for treating HER2-positive breast cancer.

The drug has been jointly developed by Biocon and US-based

generic pharmaceutical major Mylan and is expected to hit the Indian market in early February. The drug will be manufactured in Biocon's facility in Bangalore.

CANMAB will compete with Herceptin, an existing drug priced at Rs 75,000 for a 440mg vial. Herceptin is the innovator (original) product for the treatment of HER2-positive breast cancer developed by Swiss pharmaceutical company Roche. Herceptin's global sales stood at \$6.4 billion in 2012; in India the figure was \$21 million.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAB, which offers the same level of safety as the reference product (Herceptin)," said Kiran Mazumdar-Shaw, CMD, Biocon.

Publication: Times of India

Date: Jan 19, 2014

Edition: Mumbai

Biocon's breast cancer drug to hit market in Feb

Rupali Mukherjee | TNN

Mumbai: Biotechnology major Biocon on Saturday announced the launch of CANMab, a drug for the treatment of HER2-positive metastatic breast cancer.

The Bangalore-based company will sell the medicine — the first to be jointly developed with US-based generic and specialty pharma company Mylan — from February. The drug is the world's first biosimilar version of Roche's Herceptin.

Breast cancer is the most prevalent form of the disease among Indian women. Approximately 1.5 lakh new patients are diagnosed with breast cancer every year, of which nearly 25% are HER2-positive.

CANMab, Biocon says, will offer a high quality, more affordable alternative to patients in India. Roche's Herceptin costs close to an eye-popping Rs 1 lakh for a month. CANMab, being manufactured at Biocon's Bangalore facility, will be available in the Rs 19,500-57,500 range for injections of 150mg-440 mg variants respectively. The 440mg variety is 25% cheaper than the competition.

Biocon CMD Kiran Mazumdar-Shaw said: "The launch of CANMab is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product."

Biocon launches breast cancer drug in India

SANGEETHA G

Chennai

BIOTECHNOLOGY company Biocon has introduced a biosimilar of trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMab, developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Herceptin.

Available in 150 mg and 440 mg dosages, CANMab is about 25 per cent cheaper than the reference product in India. The reference

product itself is cheaper than those available in the developed markets. CANMab's 150 mg formulation, priced at Rs 19,500/vial, will help patients buy smaller quantities as per their requirement.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab, which offers the same level of safety and efficacy as the reference product. The launch of CANMab in India is an im-

portant milestone for our biosimilar programme and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product," said Kiran Mazumdar-Shaw, CMD of Biocon.

It is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously once every three weeks or on a weekly basis

depending on the patient's condition. Both 150 and 440 mg formulations can be stored for one month and this will ensure that there is no under dosing or wastage of drug, a release from Biocon said.

CANMab is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients around the first week of February 2014. Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer.

sangeethag

@mydigitalfc.com



Kiran Mazumdar-Shaw
Chief managing director
Biocon

Biocon intends to make a significant difference in the treatment paradigm

for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab™

Biocon launches cheaper breast cancer drug

Co-developed the new product with Mylan

Special Correspondent

BANGALORE: Biotechnology company Biocon on Saturday launched a new and cheaper drug to treat 'metastatic' breast cancer that aggressively spreads to other parts of the body.

The company said its product, CANMab, the world's first 'biosimilar' or remake of Swiss multinational Roche's original drug trastuzumab, would cost about 25 per cent less than the original.

Roche sells the drug in India as Herceptin, which generated 2012 sales worth around Rs.130 crore. Globally, it was around \$6.4 billion.

Biocon's tumour-targeting product is slated to enter the market in the first week of February.

It will make breast cancer treatment more affordable and accessible to many Indian patients who test positive



for the cancer-indicating HER2 (short for human epidermal growth factor), Chairman and Managing Director Kiran Mazumdar-Shaw told a news conference.

She said, "Biocon intends

to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab. [It] offers the same level of safety

and efficacy as the reference product [Herceptin.]"

The local version costs Rs.19,500 for a 50 mg budget vial and around Rs.57,000 for 400 mg. The original rival comes in a single 400 mg offer and costs around Rs.75,000-80,000, according to company officials.

Patients need to take at least three intravenous drug cycles lasting around three months before any change in tumour can be noticed. In India, breast cancer is the No. 2 cancer striking women and roughly 1.5 lakh new cases are detected each year. At least a quarter of them or nearly 40,000 test positive for the HER2 and can benefit from CANMab.

Biocon co-developed the new product with U.S. pharma major Mylan; their 2009 partnership covers four more products and a shared market.

Cheap drug to boost Biocon

Shares of Biocon will hog the limelight this week as the company launched a new and cheaper drug to treat 'metastatic' breast cancer that aggressively spreads to other parts of the body. The company said its product would cost about 25 per cent less than the original. Roche sells the drug in India as Herceptin, which generated in 2012. Sales worth around Rs 130 crore. Globally, it was around \$6.4 billion. Biocon's tumour-targeting product is slated to enter the market in the first week of February. It will make breast cancer treatment more affordable and accessible to many Indian patients who test positive for the cancer-indicating HER2 (short for human epidermal growth factor).



In focus

Biocon's cancer drug not affordable: Activists

NEW DELHI, DHNS: Indian biotechnology major Biocon's new breast cancer medicine "Canmab" is scarcely a cause for cheer as it is as costly as the original molecule "Herceptin" made by a multinational pharmaceutical company, say activists campaigning for cheaper anti-cancer medicines.

A 440 mg vial of Canmab (medical name "trastuzumab") costs about Rs 56,000, while a similar medicine of the same dose from drug major Roche would cost about Rs 75,000 in India.

Many Roche dealers already offer discounts to "steady customers", the patients needing long-term treatment. As a result, the street price of Herceptin ranges from Rs 55,000 to Rs

Canmab is the world's first biosimilar version of Herceptin, the only medicine to treat HER2 positive cases.

57,000 for a vial of 440 mg. "Biocon's price for the biosimilar is not significantly lower than what is available from Roche," said Leena Menghancy from the Campaign for Affordable Trastuzumab.

Canmab is the biosimilar version of the original medicine, developed by Roche, to treat a common type of breast cancer in which patients carry HER2 gene.

Breast cancer remains the

commonest cause of cancer among women. Approximately 1.5 lakh new Indian patients are diagnosed with breast cancer every year of which nearly 25 per cent carry HER2 gene, making them eligible for treatment with the new medicine.

Canmab is the world's first biosimilar version of Herceptin, which is the only medicine to treat HER2 positive cases.

Market tactic

The Bangalore-based company, however, has launched a 150 mg dose of the medicine, priced at Rs 19,500 per vial. "Many a times, doctors prescribe the 440 mg dose because lower dosage is not available in the market.

That's where our product will

have an edge," said a spokesperson of Biocon.

"Also, on both dosages, we offer 25 per cent discount, which will make the drug even more affordable," she told *Deccan Herald*.

Unlike the product currently available in the market, both 150 and 440 mg formulations of Canmab can be stored for a month to prevent wastage of drug which is quite common, said the spokesperson.

The activists, however, have a different take and want the medicine within a price band of Rs 5,000. "The introduction of the bio-similar will make little or no difference to women whose income is less than Rs 30,000 per month." said another activist Kalyani Menon Sen.

Biocon's 'CANMAB' to hit markets

➤ Biotechnology company Biocon will start selling breast cancer drug 'CANMAB', developed jointly with US-based Mylan, in the country from next month.

In a statement released on Saturday, the company said the drug, which would be manufactured at its biologics facility in Bangalore. CANMAB will be available at about

25 per cent discount to the current list price of the reference product - Roche's Herceptin - in India, which is already significantly lower than its price in developed markets, it added. Herceptin 440 mg, is currently sold at Rs 75,000 in the country. Biocon's product would be available in 150 mg and 440 mg strengths.

BIOCON LAUNCHES BIOSIMILAR DRUG TO TREAT BREAST CANCER

DC CORRESPONDENT
BENGALURU, JAN. 18

To address the challenge of affordability of cancer drugs, Biocon introduced CANMAb for the treatment of HER-2 positive metastatic breast cancer on Saturday. Breast cancer is the most prevalent cancer among women in the country, and nearly 1.5 lakh new patients are diagnosed with cancer every year. Of them, nearly 25 per cent cases are HER2-positive.

Biocon will make the drug available at around 25 per cent discount on the current list price of the reference product in the country.

Biocon CMD Kiran Mazumdar-Shaw said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treat-

ment with CANMAb (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product. CANMAb's launch is an important milestone for our biosimilars programme."

The drug is a targeted therapy for treating HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells.

The drug is a targeted therapy for treating HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells.

Biocon's New Breast Cancer Drug CANMAb to Hit Markets Next Month

ENS Economic Bureau

Bangalore: Biocon has announced a new drug for the treatment of HER2 positive metastatic breast cancer in the country. A biosimilar trastuzumab, CANMAb, developed jointly by Biocon and Mylan, will be the world's first biosimilar version of Herceptin and will be available in dosages of 150 mg/440 mg from February.

Global sales for Herceptin stood at \$6.4 billion in 2012 while in India sales were at \$21 million. The drug will be

manufactured at Biocon facilities in Bangalore and its price will be around 25% lesser than the current list price of the reference product in India, Biocon said.

The 150 mg formulation will be priced at ₹19,500 per vial of medicine.

Kiran Mazumdar-Shaw, MD, Biocon said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb, which offers the

same level of safety and efficacy as the reference product." Approximately 1.5 lakh new patients are diagnosed with breast cancer every year out of which 25%, according to Biocon, are HER2 positive.

It acts by interfering with HER2 protein production and stops the growth of cancer cells. It can be administered intravenously once every 3 weeks or on a weekly basis. Both versions of the drug can be stored for 1 month which will reduce underdosing or wastage.

Publication: Indian Express

Date: Jan 19, 2014

Edition: Delhi/Mumbai/Chennai/Kolkata

Biocon's breast cancer drug to hit markets next month

PRESS TRUST OF INDIA
NEW DELHI | JANUARY 18

BIOTECHNOLOGY major Biocon will start selling breast cancer drug 'CANMAB', developed jointly with US-based Mylan, in the country from next month.

The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount.

CANMAB will be available at about 25 per cent

discount to the current list price of the reference product — Roche's Herceptin — in India, which is already significantly lower than its price in developed markets, it added.

Herceptin 440 mg, is currently sold at Rs 75,000 in the country. Biocon's product would be available in 150 mg and 440 mg strengths which costs Rs 57,500. In addition, the medicine would be available in smaller quantities to make it more affordable, Biocon said.

Publication: Trinity Mirror

Date: Jan 20, 2014

Edition: Chennai

Biocon launches new breast cancer drug

Bangalore, Jan 19: Biopharmaceutical major Biocon has launched a new injectable drug for the treatment of a highly prevalent form of breast cancer and has priced its product 25 per cent lower than existing drugs in the market.

After cervical cancer, breast cancer is the most common form of cancer among Indian women, with 1.5 lakh new patients

being diagnosed with the disease every year. Of that, nearly 25 per cent are diagnosed with a particular type of breast cancer known as HER2-positive breast cancer.

This type of breast cancer is said to be the most aggressive and fast growing, having a much higher risk of early recurrence and death. Biocon's new drug, called CANMAB and priced

at Rs 57,500 for a 440 mg vial and Rs 19,500 for a 150 mg vial, has been developed for the treatment of HER2-positive breast cancer.

The drug has been jointly developed by Biocon and US-based generic pharmaceutical major Mylan and is expected to hit the Indian market in early February. The drug will be manufactured in Biocon's facility in

Bangalore.

CANMAB will compete with Herceptin, an existing drug priced at Rs 75,000 for a 440 mg vial, which is also the innovator (original) product for the treatment of HER2- breast cancer developed by Swiss pharma company Roche. The global sales for Herceptin stood at \$6.4 billion in 2012; in India it was \$21 million.

Biocon's breast cancer drug to hit markets next month

PRESS TRUST OF INDIA
NEW DELHI | JANUARY 18

BIOTECHNOLOGY major Biocon will start selling breast cancer drug 'CANMab', developed jointly with US-based Mylan, in the country from next month.

The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount.

CANMab will be available at about 25 per cent discount to the current list price of the reference prod-

uct — Roche's Herceptin — in India, which is already significantly lower than its price in developed markets, it added.

Herceptin 440mg, is currently sold at Rs 75,000 in the country. Biocon's product would be available in 150 mg and 440 mg strengths which costs Rs 57,500.

"In addition, CANMab's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement," the company said.



Biocon MD Kiran Mazumdar Shaw at an event in Bangalore Saturday.

She ruled out joining any party, saying she would rather give suggestions.

30100 b5

18111

2123

111 bns

ಸ್ವನ ಕ್ಯಾನ್ಸರ್‌ಗೆ ಜೈವಿಕ ಔಷಧ

■ ಫೆಬ್ರವರಿಯಲ್ಲಿ ಮಾರುಕಟ್ಟೆಗೆ: ಬಯೋಕಾನ್ ಫೋಷನ್

ಬೆಂಗಳೂರು: ದೇಶದಲ್ಲಿ ಹೆಚ್ಚುತ್ತಿರುವ ಮಹಿಳೆಯರ ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ಚಿಕಿತ್ಸೆಗಾಗಿ ಕಡಿಮೆ ವೆಚ್ಚದಲ್ಲಿ ಬಯೋಕಾನ್ ಸಂಸ್ಥೆಯು ಕ್ಯಾನ್‌ಮಾಬ್ (CANMab) ಎಂಬ ಔಷಧಿಯನ್ನು ಭಾರತೀಯ ಮಾರುಕಟ್ಟೆಗೆ ಅಧಿಕೃತವಾಗಿ ಬಿಡುಗಡೆ ಮಾಡಿದೆ.

150 ಗ್ರಾಂ ಮತ್ತು 440 ಗ್ರಾಂ ಪ್ಯಾಕ್‌ನಲ್ಲಿ ಲಭ್ಯವಿರುವ ಕ್ಯಾನ್‌ಮಾಬ್ ಔಷಧಿಯು ಮಹಿಳೆಯರಲ್ಲಿನ ಎಚ್

ರಾಜಕೀಯ ಪಕ್ಷ ಸೇರುವ ಯಾವುದೇ ಆಸಕ್ತಿ ಇಲ್ಲ. ಆಡಳಿತ ನಿರ್ವಹಣೆ ವೃತ್ತಿಯಿಂದ ಬಿ-ಪ್ಯಾಕ್ ಅನ್ನು ಸಂಪರ್ಕಿಸುವ ಪಕ್ಷಗಳಿಗೆ ಉತ್ತಮ ಸಲಹೆ, ಮಾರ್ಗದರ್ಶನ ಮಾಡುತ್ತೇನೆ ಹೊರತು ರಾಜಕೀಯ ಪಕ್ಷವನ್ನು ಸೇರುವುದಿಲ್ಲ.

ಕಿರಣ್ ಮಜುಂದಾರ್ ಪಾ. ಬಯೋಕಾನ್ ಮುಖ್ಯಸ್ಥೆ

ಇಆರ್‌2- ಪಾಸಿಟೀವ್ ಕ್ಯಾನ್ಸರ್ ಚಿಕಿತ್ಸೆಯಲ್ಲಿ ಪ್ರಮುಖ ಪಾತ್ರ ವಹಿಸಲಿದ್ದು, ಕ್ಯಾನ್ಸರ್ ಚಿಕಿತ್ಸೆಯಲ್ಲಿ ದೇಶದಲ್ಲೇ ಲಭ್ಯವಾಗಲಿರುವ ಮೊದಲ ಜೈವಿಕ ಔಷಧಿ ಎಂದು ಬಯೋಕಾನ್ ಅಧ್ಯಕ್ಷೆ ಕಿರಣ್ ಮಜುಂದಾರ್ ಪಾ ನಗರದಲ್ಲಿ ಸಾಂಕೇತಿಕವಾಗಿ ಔಷಧಿಯನ್ನು ಬಿಡುಗಡೆ ಮಾಡಿ ಈ ವಿಷಯ ತಿಳಿಸಿದರು.

ಮೈಲಾನ್ ಎಂಬ ಕಂಪನಿಯ ಜಂಟಿ ಸಹಭಾಗಿತ್ವದಲ್ಲಿ 2007-08ರಿಂದಲೇ ಈ ಔಷಧಿ ತಯಾರು ಮಾಡುವ ಪ್ರಯತ್ನಕ್ಕೆ ಕೈಹಾಕಿದ್ದು ಸಾಕಷ್ಟು ಪರೀಕ್ಷೆಗೆ ಒಳಪಟ್ಟ ನಂತರ ಅಂತಿಮವಾಗಿ ಮಾರುಕಟ್ಟೆಗೆ ಬಿಡುಗಡೆ ಮಾಡಲಾಗುತ್ತಿದೆ. ಫೆಬ್ರವರಿ ಮೊದಲ



ಕ್ಯಾನ್‌ಮಾಬ್ ಔಷಧಿಯೊಂದಿಗೆ ಕಿರಣ್ ಮಜುಂದಾರ್ ಪಾ.

ವಾರದಲ್ಲಿ ಈ ಔಷಧಿ ಸಾರ್ವಜನಿಕರಿಗೆ ಲಭ್ಯವಾಗಲಿದೆ. ಈ ಮೊದಲು ಹೆರಾ2-ಪಾಸಿಟೀವ್ ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ಚಿಕಿತ್ಸೆಗೆ ವಿದೇಶದಿಂದ ಔಷಧಿಗಳನ್ನು ದುಬಾರಿ ಬೆಲೆಗೆ ಆಮದು ಮಾಡಿಕೊಳ್ಳಬೇಕಾಗಿತ್ತು. ಇದೇ ಮಾದರಿಯ ಹೆರಾಸೆಪ್ಸನ್ 440 ಗ್ರಾಂ ರಾಸಾಯನಿಕ ಔಷಧಿಯ ಬೆಲೆ 75 ಸಾವಿರ ರೂ.ಗಳಾಗಿದೆ. ಅದೇ ಪ್ರಮಾಣದ ಕ್ಯಾನ್‌ಮಾಬ್ ಔಷಧಿ ಕೇವಲ 57,500 ರೂ.ಗಳಿಗೆ ಲಭಿಸಲಿದೆ ಎಂದರು.

ಮಹಿಳೆಯರ ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ಚಿಕಿತ್ಸೆಯಲ್ಲಿ ಈ ಔಷಧಿ ಮಹತ್ವದ ಮೈಲುಗಲ್ಲಾಗಲಿದೆ. 150 ಗ್ರಾಂನಲ್ಲೂ ಸಿಗುವ ಕ್ಯಾನ್‌ಮಾಬ್ ಔಷಧಿ 19,500 ರೂ.ಗೆ ಲಭ್ಯವಾಗಲಿದೆ. ಮಧ್ಯಮ ವರ್ಗ ಗಮನದಲ್ಲಿ ಇಟ್ಟುಕೊಂಡು ಕೈಗೆಟುಕುವ ದರದಲ್ಲಿ ಔಷಧಿಯನ್ನು ಸಂಸ್ಥೆ ತಯಾರು ಮಾಡಿದೆ ಎಂದರು.

150 ಎಂಎಲ್ ಬೆಲೆ 19500 ರೂ.

ಸ್ವನ ಕ್ಯಾನ್ಸರ್‌ಗೆ 'ಅಗ್ಗ'ದ ಔಷಧಿ

- ಬಯೋಕಾನ್‌ನಿಂದ ಔಷಧಿ ಬಿಡುಗಡೆ
- ಇತರೆ ಕಂಪನಿಗಳ ದರಕ್ಕಿಂತ ಶೇ.25 ಕಮ್ಮಿ



ಬೆಂಗಳೂರು: ಔಷಧ ಸಂಶೋಧನೆ ಕ್ಷೇತ್ರದಲ್ಲಿ ಮುಂಚೂಣಿಯಲ್ಲಿರುವ ಬಯೋಕಾನ್ ಸಂಸ್ಥೆಯು ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ನಿವಾರಣೆಗಾಗಿ 'ಕ್ಯಾನ್‌ಮ್ಯಾಬ್' ಎಂಬ ಔಷಧಿಯನ್ನು ಮಾರುಕಟ್ಟೆಗೆ ಪರಿಚಯಿಸಿದೆ.

ಈ ಕುರಿತು ಶನಿವಾರ ನಡೆದ ಸುದ್ದಿಗೋಷ್ಠಿಯಲ್ಲಿ ಮಾಹಿತಿ ನೀಡಿದ ಬಯೋಕಾನ್ ಮುಖ್ಯಸ್ಥೆ ಕಿರಣ್ ಮಜುಂದಾರ್ ಶಾ, ಪ್ರಸ್ತುತ 150 ಮಿಲಿ ಗ್ರಾಂ ಹಾಗೂ 450 ಮಿಲಿ ಗ್ರಾಂ ಪ್ರಮಾಣದಲ್ಲಿ ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ಗೆ ಪರಿಣಾಮಕಾರಿಯಾಗಬಲ್ಲ ಈ ಔಷಧಿಯನ್ನು ಮಾರುಕಟ್ಟೆಗೆ ಪರಿಚಯಿಸಲಾಗುತ್ತಿದೆ. ಈಗಾಗಲೇ ಮಾರುಕಟ್ಟೆಯಲ್ಲಿ ಲಭ್ಯವಿರುವ ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ಔಷಧಿಗಳ ದರಕ್ಕಿಂತ ಶೇಕಡೆ 25 ರಷ್ಟು ಕಡಿಮೆ ಬೆಲೆಯಲ್ಲಿ ಇದು ದೊರೆಯಲಿದೆ ಎಂದು ಹೇಳಿದರು.

ಫೆಬ್ರವರಿಯಲ್ಲಿ ಔಷಧಿಯು ಮಾರುಕಟ್ಟೆಯಲ್ಲಿ ಲಭ್ಯವಾಗಲಿದ್ದು

150 ಮಿಲಿ ಗ್ರಾಂ ಔಷಧಿಗೆ 19,500 ರೂ. ಹಾಗೂ 450 ಮಿಲಿ ಗ್ರಾಂಗೆ 57 ಸಾವಿರ ರೂ. ಬೆಲೆ ನಿಗದಿ ಮಾಡಲಾಗಿದೆ. ಈಗಾಗಲೇ ಮಾರುಕಟ್ಟೆಯಲ್ಲಿರುವ 440 ಮಿಲಿ ಗ್ರಾಂ ಔಷಧಿಗೆ 75 ಸಾವಿರ ರೂ. ಗೂ ಹೆಚ್ಚು ಹಣ ವಡೆಯಲಾಗುತ್ತಿದೆ. ಹೀಗಾಗಿ, ಬಯೋಕಾನ್‌ನ ಈ ಔಷಧಿ ನೂತನ ಮೈಲುಗಲ್ಲಾಗಲಿದೆ ಎಂದು ಅಭಿಪ್ರಾಯಪಟ್ಟರು.

ಪ್ರಸ್ತುತ ಭಾರತದ ಮಾರುಕಟ್ಟೆಗೆ ಮಾತ್ರ ಔಷಧಿ ಬಿಡುಗಡೆ ಮಾಡುತ್ತಿದ್ದು, ಭಾರತದಲ್ಲಿ ಸೂಕ್ತ ಚಿಕಿತ್ಸೆ ದೊರೆಯದೆ ಸಮಸ್ಯೆ ಎದುರಿಸುತ್ತಿರುವ 1.45 ಲಕ್ಷ ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ರೋಗಿಗಳಿಗೆ ಇದರಿಂದ ನೆರವಾಗಲಿದೆ. ಈಗಾಗಲೇ ಯೂರೋಪ್ ಹಾಗೂ ಅಮೆರಿಕ ದೇಶಗಳಿಗೆ ಔಷಧಿ ಪೂರೈಕೆ ಮಾಡಲು ಅನುಮತಿಗೆ ಮನವಿ ಸಲ್ಲಿಸಲಾಗಿದ್ದು ಆ ದೇಶಗಳಿಗೂ ಔಷಧಿವನ್ನು ರಫ್ತು ಮಾಡಲಾಗುವುದು ಎಂದರು.

ಸ್ವನ ಕ್ಯಾನ್ಸರ್‌ಗೆ ಕ್ಯಾನ್‌ಮ್ಯಾಚ್

ಹೊಸ ಔಷಧ ಫೆಬ್ರವರಿಯಲ್ಲಿ ಮಾರುಕಟ್ಟೆಗೆ: ಕಿರಣ್ ಮುಜುಂದಾರ್ ಶಾ

ಕನ್ನಡಪ್ರಭ ವಾರ್ತೆ, ಬೆಂಗಳೂರು, ಜ.18
ಸ್ವನ ಕ್ಯಾನ್ಸರ್‌ಗೆ 'ಕ್ಯಾನ್‌ಮ್ಯಾಚ್' ಎಂಬ ನೂತನ ಔಷಧವನ್ನು ಪ್ರತಿಷ್ಠಿತ ಬಯೋಟಾಕ್ ಸಂಸ್ಥೆ ಬಿಡುಗಡೆಗೊಳಿಸಿದೆ.

ಪ್ರಸ್ತುತ ಮಾರುಕಟ್ಟೆಯಲ್ಲಿರುವ ಬಯೋಸಿಮಿಲರ್ ಔಷಧಕ್ಕಿಂತ ಶೇ.25ರಷ್ಟು ಕಡಿಮೆ ದರದಲ್ಲಿ ಇದು ಲಭ್ಯವಾಗುತ್ತಿದೆ. ಫೆಬ್ರವರಿ ಮೊದಲ ವಾರ ದಿಂದ ಭಾರತೀಯ ಮಾರುಕಟ್ಟೆಯಲ್ಲಿ ಇದು ಲಭ್ಯವಿರಲಿದೆ ಎಂದು ಬಯೋಟಾಕ್ ಅಧ್ಯಕ್ಷ ಕಿರಣ್ ಮುಜುಂದಾರ್ ಶಾ ಹೇಳಿದ್ದಾರೆ.

ನಗರದಲ್ಲಿ ಕೂವಾರ 'ಕ್ಯಾನ್‌ಮ್ಯಾಚ್' ಔಷಧ ಬಿಡುಗಡೆಗೊಳಿಸಿ ಮಾತನಾಡಿದ ಅವರು, 'ಕ್ಯಾನ್‌ಮ್ಯಾಚ್' ಔಷಧ 150 ಎಂಜಿ ಹಾಗೂ 440 ಎಂಜಿ ಪ್ರಮಾಣದಲ್ಲಿ ಲಭ್ಯವಿದ್ದು, ಕ್ರಮವಾಗಿ ₹19,500 ಹಾಗೂ ₹57 ಸಾವಿರ ಮುಖಬೆಲೆ ಹೊಂದಿದೆ. ಪ್ರಸ್ತುತ ಮಾರುಕಟ್ಟೆಯಲ್ಲಿರುವ ಇತರ ಔಷಧಗಳಿಗಿಂತ ಇದು ಶೇ.25ರಷ್ಟು ಕಡಿಮೆ ಬೆಲೆ ಹೊಂದಿದೆ ಎಂದು ತಿಳಿಸಿದರು.

ಭಾರತದಲ್ಲಿ ಪ್ರತಿ ವರ್ಷ 1.45 ಲಕ್ಷ ಸ್ವನ ಕ್ಯಾನ್ಸರ್ ಪ್ರಕರಣ ಬೆಳಕಿಗೆ ಬರುತ್ತಿದೆ. ಆದರೆ ಬಹು ಕೇಳಿಗೆ ಬಹಿಷ್ಕಾ ವೆಚ್ಚ ಭರಿಸುವುದೇ ಕಷ್ಟವಾಗುತ್ತಿದೆ. ಈ ಮೊದಲು ಔಷಧ ಕೇವಲ 440 ಎಂಜಿ ಪ್ರಮಾಣದಲ್ಲಿ ಲಭ್ಯವಿರುತ್ತಿತ್ತು. ಇದರಿಂದ ಕಡಿಮೆ ಪ್ರಮಾಣ ಅಗತ್ಯವಿರುವ ರೋಗಿಯು ₹75 ಸಾವಿ

ಬಯೋಸಿಮಿಲರ್ ಔಷಧಕ್ಕಿಂತ ಶೇ.25ರಷ್ಟು ಕಡಿಮೆ ದರದಲ್ಲಿ ಲಭ್ಯ ಮಾರುಕಟ್ಟೆಯ ಇತರ ಔಷಧಗಳಿಗಿಂತ ಶೇ.25ರಷ್ಟು ಕಡಿಮೆ ಬೆಲೆ



ರಕ್ಕೂ ಅಧಿಕ ಹಣ ವ್ಯಯಿಸುವ ಅಗತ್ಯವಿತ್ತು. ಈ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ದರ ಕಡಿಮೆ ಮಾಡಿ ಕಡಿಮೆ ಪ್ರಮಾಣದಲ್ಲಿಯೂ ಔಷಧ ಲಭ್ಯವಿರುವ ವ್ಯವಸ್ಥೆ ಮಾಡಲಾಗಿದೆ ಎಂದು ಅವರು ಹೇಳಿದರು.

ಈ ಔಷಧವನ್ನು ಯುರೋಪ್ ಹಾಗೂ ಅಮೆರಿಕ ಮಾರುಕಟ್ಟೆಗೂ ವಿಸ್ತರಿಸಲು ಅನುಮತಿ ಕೇಳಲಾಗಿದೆ. ಕಳೆದ 2008ರಿಂದ ನಡೆಸುತ್ತಿದ್ದ ಸಂಶೋ

ಧನೆಗೆ ಫಲ ದೊರೆತಿದ್ದು, ವಿಶ್ವಮಟ್ಟದಲ್ಲಿ ಸಂಸ್ಥೆ ಇನ್ನಷ್ಟು ಬೆಳೆಯಲು ಇದು ನೆರವಾಗಲಿದೆ ಎಂದು ಅವರು ಅಭಿಪ್ರಾಯಪಟ್ಟರು.

ಯಾವ ಪಕ್ಷವನ್ನು ಸೇರಲು: ಆಮ್. ಅದ್ವಿ ಪಕ್ಷ ಸೇರಿದಂತೆ ಯಾವುದೇ ರಾಜಕೀಯ ಪಕ್ಷವನ್ನೂ ನಾನು ಸೇರುವುದಿಲ್ಲ ಅಥವಾ ಬೆಂಬಲಿಸುವುದೂ ಇಲ್ಲ ಎಂದು ಕಿರಣ್ ಮುಜುಂದಾರ್ ಶಾ ಸ್ಪಷ್ಟಪಡಿಸಿದ್ದಾರೆ.

ನಾನು ಆಮ್ ಅದ್ವಿ ಪಕ್ಷ ಸೇರುತ್ತೇನೆ ಎನ್ನುವುದೆಲ್ಲ ಉಪಾಪೋಹ. ಪಕ್ಷದ ಕೈಗಾರಿಕೆ ಹಾಗೂ ಅರ್ಥಿಕ ನೀತಿಗೆ ಸಂಬಂಧಿಸಿ ಪ್ರಣಾಳಿಕೆ ತಯಾರಿಸಲು ನನ್ನ ಸಲಹೆ ಕೇಳಿರುವುದು ನಿಜ. ಹಾಗೆಂದ ಮಾತ್ರಕ್ಕೆ ನಾನು ಆಮ್ ಅದ್ವಿ ಸೇರುತ್ತೇನೆ ಎನ್ನುವುದು ಗಾಳಿ ಸುದ್ದಿ. ಯಾವುದೇ ಪಕ್ಷ ಈ ಸಂಬಂಧ ಅಭಿಪ್ರಾಯ ಕೇಳಿದರೆ ಹಂಚಿಕೊಳ್ಳುತ್ತೇನೆ. ರಾಜ್ಯದ ಪ್ರಮುಖ ಕೈಗಾರಿಕೋದ್ಯಮಿಯಾಗಿ ಎಲ್ಲ ಪಕ್ಷಗಳಿಗೂ ನನ್ನ ಸಲಹೆ ಹಾಗೂ ಅಭಿಪ್ರಾಯ ತಿಳಿಸುತ್ತೇನೆ. ಆದರೆ ಆಯಾ ಪಕ್ಷಗಳು ಸಂಪರ್ಕಿಸಿದರೆ ಮಾತ್ರ ಎಂದು ಅವರು ಅಭಿಪ್ರಾಯಪಟ್ಟರು.

ಇದೇ ಸಂದರ್ಭದಲ್ಲಿ ಅವರು ನಂದನ್ ನೀಲೇ ಕಣೆ ಅವರು ರಾಜಕೀಯಕ್ಕೆ ಪ್ರವೇಶಿಸುತ್ತಿರುವುದನ್ನು ಸಮರ್ಥಿಸಿ, ದೇಶದ ಅಭಿವೃದ್ಧಿ ಕುರಿತಂತೆ ಪರಿಕಲ್ಪನೆ ಹೊಂದಿರುವ ವ್ಯಕ್ತಿ ರಾಜಕೀಯಕ್ಕೆ ಬರುವುದು ಉತ್ತಮ ಬೆಳವಣಿಗೆ ಎಂದು ವ್ಯಾಖ್ಯಾನಿಸಿದ್ದಾರೆ.



► 108806 ಪ್ರಸ್ತುತ ಮಾರುಕಟ್ಟೆಯಲ್ಲಿರುವ ಬಯೋಸಿಮಿಲರ್ ಔಷಧಕ್ಕಿಂತ ಶೇ.25ರಷ್ಟು ಕಡಿಮೆ ದರದಲ್ಲಿ ಇದು ಲಭ್ಯವಾಗುತ್ತಿದೆ. ಫೆಬ್ರವರಿ ಮೊದಲ ವಾರ ದಿಂದ ಭಾರತೀಯ ಮಾರುಕಟ್ಟೆಯಲ್ಲಿ ಇದು ಲಭ್ಯವಿರಲಿದೆ ಎಂದು ಬಯೋಟಾಕ್ ಅಧ್ಯಕ್ಷ ಕಿರಣ್ ಮುಜುಂದಾರ್ ಶಾ ಹೇಳಿದ್ದಾರೆ.

రోమ్ము కేన్సర్ చికిత్సకు బయోకాన్ తక్కువ ధర మండు

ఈనాడు, బెంగళూరు: రోమ్ము కేన్సర్ చికిత్సలో ఉపయోగించే క్యాన్మాట్ బిషడాన్ని బయోకాన్ తీసుకువచ్చింది. ఈ బిషడాన్ని బయోకాన్ ఆమెరికాకు చెందిన మైలాన్తో కలిసి అభివృద్ధి చేసింది. ఫిబ్రవరి ఒకటో వారం నుంచి దేశవ్యాప్తంగా ఈ మందును విక్రయించనున్నట్లు కనివారం ప్రకటించింది. 150 మిల్లీ గ్రాములు, 440 మి.గ్రా. లలో క్యాన్మాట్ అభ్యం కానుంది. బెంగళూరులోని తమ జీవ వైజ్ఞానిక కేంద్రంలో ఈ బిషడాన్ని తయారు చేసి, తగ్గింపు ధరకే అందించనున్నట్లు బయోకాన్ తెలిపింది. దీనికి సమూహ బిషధం రాష్ట్రం చెందిన హార్సిస్టిన్ ఇది అభివృద్ధి చెందిన మార్కెట్లో అభ్యంతున్న ధరతో పోలిస్తే తక్కువ ధరకు వారంలో అభ్యంతుతోంది. ఈ తక్కువ ధరే ప్రస్తుతం రూ.75,000 అంచా ఇంత కన్నా చాలాపు 25% తక్కువ ధరకు, రూ.57,500 కు క్యాన్మాట్ బిషడాన్ని వారంలో అందుబాటులోకి తీసుకురానున్నట్లు బయోకాన్ వివరించింది. రోగులు వారి ఆవసరాలికి తగ్గట్టుగా తక్కువ మోతాదులో కాసుగోలు చేసేందుకు రూ.150 మి.గ్రా. సిసాసు (వైల్) రూ.18,500కు అందిస్తున్నట్లు తెలిపింది. ఈపం



తనివారం బెంగళూరులో క్యాన్మాట్ బిషడాన్ని లాంఛంగా అవిష్కరిస్తున్న కిరణ్ మజుందార్ షా తరతులు

ధ్యంగా బయోకాన్ సీఎండ్ కిరణ్ మజుందార్ షా బెంగళూరులో మాట్లాడుతూ ఈ బిషడాన్ని హెచ్ఈఆర్2 ఫాతిమా ఉస్మా మహిళలకు తీవ్ర తమ బట్టి వాడాలన్నారు. దేశ వ్యాప్తంగా ఏదానికి లక్ష మందికి పైగా మహిళలు ఈ కేన్సర్ వారిన పడి మరణిస్తున్నారని అమె చెప్పారు.

రోమ్ము కేన్సర్ కు దేశీయ ఔషధం.



కాన్మాట్ను అవిష్కరిస్తున్న కిరణ్ మజుందార్ షా

సాక్షి ప్రతినిధి, బెంగళూరు: రోమ్ము కేన్సర్ చికిత్సకు దేశీయ కంపెనీ బిషధం కూడా అందుబాటులోకి రానుంది. ప్రముఖ బిషధ రంగ సంస్థ బయోకాన్ రోమ్ము(వ్రన) కేన్సర్ చికిత్స కోసం 'కాన్మాట్' అనే నూది మందును అవిష్కరించింది. బయోకాన్ ఏండ్, చైర్పర్సన్ కిరణ్ మజుందార్ షా ఈ మేరకు కనివార మిక్కడ విలేజరులకు వివరాలు చెల్లడించారు. కాన్

- బయోకాన్ నుంచి కాన్మాట్
- ప్రస్తుత వినియోగ బిషధ ధరతో పోల్చితే 25 శాతం తక్కువ

మాట్ బిషధం ఫిబ్రవరి తొలివారం నుంచి అందుబాటులోకి రానుంది. ఇప్పటివరకూ ఆమెరికా సంస్థ తయారు చేసిన 'హార్సిస్టిన్' అనే బిషడాన్ని దేశంలో వాడుతున్నారు. ఆ మందు ధర రూ.75 వేలు కాగా, కాన్మాట్ ధర 25 శాతం తక్కువ. కాన్మాట్ బిషధం 150 మిల్లీగ్రాముల మోతాదు ధరను రూ.18,500గా, 440 మిల్లీగ్రాముల ధరను రూ.57,500గా నిర్ణయించారు. వ్యాధిస్థాయిని బట్టి, ఈ బిషధంతో తెండు నుంచి మూడు నెలల్లో కేన్సర్ కణికి పరిమాణాన్ని తగ్గించడం లేదా పూర్తిగా నిర్మూలించడం సాధ్యమవుతుందని షా తెలియజేశారు. ప్రస్తుతం దేశంలో ఈ బిషడానికి రూ.130 కోట్ల మేరకు మార్కెట్ ఉంది.



बायोवॉर्कन बायोटेकनोलॉजी लि. की चेयरपर्सन और एमडी किरण मजूमदार शॉ बेंगलूरु में दुनिया के पहले बायोसिमिलर ट्रस्युजुमाब ब्रेस्ट कैंसर इंजेक्शन 'केनमाब' लॉन्च करती हुई।

अच्छी खबर

तुलसी की जेनेटिक इंजीनियरिंग में जुटे अमेरिकी वैज्ञानिक

तुलसी के औषधीय गुण बढ़ाने की कवायद

एजेंसी, वॉशिंगटन

अमेरिका के वैज्ञानिक तुलसी की जेनेटिक इंजीनियरिंग में लगे हैं। ताकि कैंसर जैसी बीमारियों के इलाज के लिए इससे बेहतर दवाई बनाई जा सके।

तुलसी पर ये शोध अमेरिकी यूनिवर्सिटी में हो रहा है लेकिन टीम के मुखिया भारतीय मूल के चंद्रकांत ईमानी हैं। ईमानी अमेरिका की वेस्टर्न केंटकी यूनिवर्सिटी में प्लांट मोलिक्यूलर बायोलॉजी के असिस्टेंट प्रोफेसर हैं। उनकी टीम तुलसी के पौधे में मौजूद कंपाउंड यूजेनॉल का

उत्पादन बढ़ाने पर काम कर रही है। यूजेनॉल अब तक ब्रेस्ट कैंसर को रोकने में काफी कारगर रहा है। ईमानी का कहना है कि काफी समय पहले एक प्रयोग किया गया था।

तुलसी के पत्तों को पीसने से निकले यूजेनॉल ने ट्रस्युमर सेल्स की ग्रोथ रोक दी थी। हम सफल रहे तो तुलसी के पौधे को कैंसर-रोधी कंपाउंड के स्टोरहाउस के तौर पर विकसित कर सकेंगे। भारत समेत पूर्वी देशों में तुलसी का इस्तेमाल आम है। यह कई रोगों है। ईमानी ने बताया कि हमारे शोध का अगला चरण इससे कैंसर रोधी दवा बनाना होगा। हमें लगता है कि इसमें कामयाबी मिलेगी।

किरण मजूमदार की कंपनी ने बनाई स्तन कैंसर की नई दवा

बेंगलूरु, स्तन कैंसर की नई दवा इजाद करने का दवा किया गया है। इसे महिला उद्यमी किरण मजूमदार शॉ की बायोफार्मास्युटिकल्स कंपनी बायोवॉर्कन ने बनाया है। इसकी कीमत मौजूद दवाओं के मुकाबले 25 फीसदी कम रखी गई है। भारतीय महिलाएं सर्जिकल कैंसर के बाद सबसे ज्यादा ब्रेस्ट कैंसर की शिकार होती हैं। हर साल 1.5 लाख महिलाओं को स्तन कैंसर होता है। इनमें से 25 फीसदी महिलाओं को एचईआर-2 पॉजिटिव ब्रेस्ट कैंसर होता है। यह सबसे घातक और सबसे तेजी से फैलने वाला कैंसर है। बायोवॉर्कन ने 'केनमाब' दवा बनाई है। कीमत 440 एमजी के लिए 57500 रुपए और 150 एमजी के लिए 19500 रुपए रखी गई है।

'அரசியல் கட்சிகளில் சேரப் போவதில்லை'

பெங்களூரு தன: 18: ஆம் ஆத்மி உள்விட்ட எந்த அரசியல் கட்சிகளிலும் சேரப் போவதில்லை என்று, பியோகான் நிறுவனத் தலைவர், மேலாண் இயக்குநர் கிரீன் மஜும்தாரிஷா தெரிவித்தார்.

பெங்களூருவில் சனிக்கிழமை அந்த நிறுவனம் சார்பில் தயாரிக்கப்பட்ட மாப்புழந்துறையக்கான மருத்துவ அறிமுகம் செய்த பிறகு, செயல்பாளர்களில் சேரவில்லை என்று தெரிவித்து அவர் பேசினார்.

ஆம் ஆத்மி கட்சி உள்விட்ட வேறு எந்த அரசியல் கட்சிகளும் சேரும் எண்ணம் இல்லை. நல்ல அரசு நிர்வாகம், கொடுக்காத தாராள உட்கட்டமைப்பிற்காக அரசியல் கட்சிகளுக்கு ஆலோசனைக் கூறும் பங்களிப்பை எப் போதும் போல தொடருவேன்.

அரசியலில் மாற்றத்தை கொண்டுவர விரும்புவோர் அரசியலில் ஈடுபடுவதை விரைவில் வேண்டும்.

அரசியல் உள்விட்ட அமைத்துத் துறைகளில் புதுமையான மாற்றத்தை கொண்டுவர விரும்பும் பியோகான் நடுத்தல் நிர்வாகியும் ஒருவர்.

அவரிடம் புதிதாகிந்தவரைய தொடர்புடைய செய்தி தெரிவித்தார்.



பெங்களூருவில் சனிக்கிழமை பியோகான் நிறுவனம் தயாரித்துள்ள மாப்புழந்துறையக்கான மருத்துவ அறிமுகம் செய்துகொடுத்த நிறுவனத்தின் தலைவர் கிரீன் மஜும்தாரிஷா, உட்கட்டமைப்பிற்கான உட்கட்டமைப்பை செய்து அதிசயி அனைத்துவகையிலும் உள்விட்டார்.

தலைவர் உள்விட்டார். தொழில் துறையில் மாற்றம் இல்லாத வெளிப்பாட்டையே அழகுத்துறை கொண்டுவர வேண்டும். குறிப்பாக அரசியல் உள்விட்டார். கொடுக்காமல் ஒரு சிலர் பயன்பாட்டிற்காக, அமைப்புகளும் சமமான வளங்களைக் கொடுக்க வேண்டும்.

இதுபோன்ற பிரச்சனைகளுக்கு தீர்வு காண வேண்டும். உள்விட்டார் தொழில் துறைகளில் மாற்றத்தை கொண்டுவர வேண்டும். ஆம் ஆத்மி கட்சி உள்விட்டார் அமைத்து கட்சிகளும் சாதாரணமாக ஒழுங்குபடுத்தி கொண்டுவர முயற்சிக்க வேண்டும் என்றார் அவர்.

बायोकाॅन ने लॉन्च की ब्रेस्ट कैंसर की सस्ती दवा

[ईटी ब्यूरो, नई दिल्ली]

जानीमानी बायोटेक्नोलॉजी कंपनी बायोकाॅन ने कहा है कि वह भारत में अगले महीने से एंटी-ब्रेस्ट कैंसर ड्रग केनमैब बेचना शुरू करेगी। यह स्विटजरलैंड की कंपनी रोसा की दवा हरसेप्टिन का बायोसिमिलर वर्जन है।

बायोकाॅन ने यह दवा अमेरिका की मायलन के साथ मिलकर तैयार की थी। उसे पिछले साल भारतीय ड्रग रेगुलेटर की मंजूरी मिली थी। बायोकाॅन की दवा की एक बायल 19,500 रुपये की होगी। हरसेप्टिन का दाम 75,000 रुपये है। बायोकाॅन की सीएमडी किरण मजूमदार शॉ ने एक स्टेटमेंट में कहा कि भारत में केनमैब की लॉन्चिंग हमारे बायोसिमिलर प्रोग्राम के लिए मोल का पत्थर है और



इससे हाई-क्वालिटी
वर्ल्ड क्लास प्रॉडक्ट को
अफोर्डेबल प्राइस में पेश
करने की हमारी क्षमता
का पता भी चलता है।
बयान में कहा गया
कि यह दवा भारत में
इसे रेफरेंस प्रॉडक्ट की
मौजूदा लिस्ट प्राइस
से काफी डिस्काउंट
पर उपलब्ध होगी।
बायोर्कॉन ने कहा कि

हरसेप्टिन
का जेनेरिक
वर्जन 19500
रुपये में बेचेगी
बायोर्कॉन

यह दवा कंपनी के बंगलुरु वाले कारखाने
में तैयार की जाएगी। उसने कहा कि दवा
फरवरी के पहले सप्ताह में मरीजों को
मिलने लगेगी।

माना जाता है कि रोश की हरसेप्टिन
एचईआर 2 कैंसर सेल को टारगेट करने के
मामले में सबसे ज्यादा प्रभावी है। एचईआर 2
सेल के कारण ही ब्रेस्ट कैंसर होता है। पिछले
साल अगस्त में रोश ने भारत में हरसेप्टिन
का पैटेंट आगे नहीं बढ़ाने का फैसला किया
था। इसके चलते दूसरी जेनेरिक ड्रग मेकर्स
के लिए इसे तैयार करने का रास्ता साफ हो
गया था। इस दवा को तैयार करने की प्रक्रिया
काफी जटिल है, लिहाजा बायोर्कॉन और
रोश को छोड़कर कोई और कंपनी इसे नहीं
बनाती है। रोश भी इसे भारत में तैयार करती
है। हालांकि, मुंबई को बीडीआर फार्मा भी अब
हरसेप्टिन के जेनेरिक वर्जन के लिए शोध
कर रही है।

Publication: Dainik Tribune

Date: Jan 19, 2014

स्तन कैंसर दवा जल्द
दिल्ली (भाषा) : स्तन कैंसर के
मरीजों के लिए अच्छी खबर है।
बायोटेक्नॉलाजी क्षेत्र की प्रमुख
कंपनी बायोर्कॉन देश में अगले
महीने से स्तन कैंसर के इलाज में
कम आने वाली दवा 'कैनमैब' की
बिक्री शुरू करेगी। इसका निर्माण
उसने अमेरिका की कंपनी मायलैन
के साथ मिलकर किया है। बायोर्कॉन
लिमिटेड ने यहां जारी एक बयान में
कहा कि कंपनी ने बेंगलूर स्थित
संपंत्र में इस दवा का निर्माण किया
और इसकी बिक्री रोगियों को
रियायती दर पर की जाएगी। कंपनी
ने कहा कि भारत में कैनमैब करीब
25 फीसदी रियायत पर उपलब्ध
होगी। बयान में कहा गया कि कंपनी
फरवरी 2014 के पहले सप्ताह में
रोगियों को दवा की बिक्री शुरू
करेगी। हर साल स्तन कैंसर के क-
रीब डेढ़ लाख नए रोगी सामने आते
हैं जिनमें से करीब 25 फीसदी
मामलों में कैनमैब के जरिए इलाज
किया जा सकता है।

Publication: Anand Bazaar Patrika

Date: Jan 20, 2014

Edition: Kolkata

ক্যালারের ওষুধ

ফেব্রুয়ারি মাসেই দেশের বাজারে
স্তন ক্যালারের নতুন ওষুধ বিক্রি
শুরু করতে চলেছে বায়োকন।
স্বিডেশি সংস্থা রোসে-র তৈরি
হার্শেপটিন ওষুধটির জেনেরিক
সংস্করণ বাজারে আনবে বেঙ্গালুরু
ভিত্তিক এই ওষুধ নির্মাতা। গত
নভেম্বরেই মার্কিন মাইল্যান-এর
সঙ্গে যৌথ উদ্যোগে এই নতুন
ওষুধ তৈরি করার অনুমতি
পেয়েছে বায়োকন।

Publication: Dainik Viswamitra

Date: Jan 20, 2014

Edition: Kolkata

बायोकांन ने भारतीय बाजार में उतारी स्तन कैंसर की दवा

मुम्बई, १८ जनवरी (एजेंसियां)।
फार्मा क्षेत्र की देश की दिग्गज कंपनी
बायोकांन ने स्तन कैंसर के उपचार में
इस्तेमाल होने वाली 'कैनमैब'
भारतीय बाजार में उतारी है। बायोकांन
ने एक बयान में कहा है कि कंपनी और
उसके वैश्विक भागीदार मिलान द्वारा
तैयार की गई दवा कैनमैब स्तन कैंसर
से पीड़ित मरीजों के लिए १५०
मिलीग्राम और ४०० मिलीग्राम में
उपलब्ध होगी। कंपनी ने कहा कि
कैनमैब की कीमत स्तन कैंसर के
इलाज के लिए बाजार में उपलब्ध
'हरसेप्टिन' से करीब २५ प्रतिशत कम
रखी है। बायोकांन की अध्यक्ष सह
प्रबंध निदेशक किरण मजूमदार शा ने
कहा कि भारत में स्तन कैंसर के मामलों
को तेजी से हो रही वृद्धि के मद्देनजर
कंपनी कैनमैब को अधिक से अधिक
पीड़ितों तक पहुंचना चाहती है।

Online Coverage:

THE ECONOMIC TIMES

Biocon's breast cancer drug 'CANMAB' to hit markets next month

PTI Jan 18, 2014, 03.57PM IST

http://articles.economictimes.indiatimes.com/2014-01-18/news/46324991_1_breast-cancer-drug-herceptin-canmab

NEW DELHI: Biotechnology major Biocon will start selling breast cancer drug 'CANMAB', developed jointly with US-based Mylan, in the country from next month.

The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount, Biocon Ltd said in a statement.

CANMAB will be available at about 25 per cent discount to the current list price of the reference product - Roche's Herceptin - in India, which is already significantly lower than its price in developed markets, it added.

Herceptin 440mg, is currently sold at Rs 75,000 in the country. Biocon's product would be available in 150 mg and 440 mg strengths, which costs Rs 57,500.

"In addition, CANMAB's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement," the company said.

The company would start selling the drug to patients around the first week of February 2014, it added. Around 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25 per cent cases are eligible for treatment with CANMAB.

Commenting on the launch, Biocon Ltd CMD Kiran Mazumdar-Shaw said: "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAB (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product."

CANMAB, which has been developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Roche's Herceptin drug.

"Both 150 and 440 mg formulations of CANMAB can be stored for one month which is an important offering for patients in India, as it will ensure that there is no under-dosing or wastage of drug which is quite common today," the company said.

The global sales for Herceptin stood at \$ 6.4 billion in 2012, while in India it recorded sales of \$ 21 million.

Biocon launches breast-cancer drug CANMAb

By ET Bureau | 19 Jan, 2014, 04.00AM IST

<http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/biocon-launches-breast-cancer-drug-canmab/articleshow/29020528.cms>

MUMBAI: Bangalore-based drugmaker Biocon on Saturday launched CANMAb, the biosimilar version of anti-cancer drug Herceptin, a move that analysts say would be a high revenue generator for the company. Biocon which developed the drug in association with US drugmaker Mylan received the approval last year.

Originally developed by Swiss drugmaker Roche the drug is believed to be one the most effective medicines in targeting the HER 2 cancer cell, which leads to breast cancer. Priced at Rs 19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.

"The launch of CANMAb in India is an important milestone for our biosimilar programme and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world- class product," said Kiran Mazumdar Shaw in a press statement."

Biocon said the drug will be manufactured at the company's Bangalore facility and will be available to patients around the first week of February 2014. CANMAb will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets, according to the company.

In August last year Roche decided not to pursue the Herceptin patent in India and paved the way for other generic makers to manufacture the drug. Since the science involved in producing the drug is complex, there are no other players apart from Biocon and Roche which manufacture this drug in India. The other company which is researching on generic Herceptin is Mumbai-based BDR Pharma.

THE TIMES OF INDIA

Kiran Mazumdar-Shaw's Biocon develops new breast cancer drug

Anshul Dhamija, TNN | Jan 18, 2014, 08.06PM IST

<http://timesofindia.indiatimes.com/business/india-business/Kiran-Mazumdar-Shaws-Biocon-develops-new-breast-cancer-drug/articleshow/29016754.cms>

BANGALORE: Biopharmaceutical major Biocon has launched a new injectable drug for the treatment of a highly prevalent form of breast cancer and has priced its product 25 per cent lower than existing drugs in the market.

After cervical cancer, breast cancer is the most common form of cancer among Indian women, with 1.5 lakh new patients being diagnosed with the disease every year. Of that, nearly 25 per cent are diagnosed with a particular type of breast cancer known as HER2-positive breast cancer.

This type of breast cancer is said to be the most aggressive and fast growing, having a much higher risk of early recurrence and death. Biocon's new drug, called CANMAb and priced at Rs 57,500 for a 440 mg vial and Rs 19,500 for a 150 mg vial, has been developed for the treatment of HER2-positive breast cancer.

The drug has been jointly developed by Biocon and US-based generic pharmaceutical major Mylan and is expected to hit the Indian market in early February. The drug will be manufactured in Biocon's facility in Bangalore.

CANMAb will compete with Herceptin, an existing drug priced at Rs 75,000 for a 440 mg vial, which is also the innovator (original) product for the treatment of HER2- breast cancer developed by Swiss pharma company Roche. The global sales for Herceptin stood at \$6.4 billion in 2012; in India it was \$21 million.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb, which offers the same level of safety and efficacy as the reference product (Herceptin)," said Kiran Mazumdar-Shaw, CMD, Biocon.

THE TIMES OF INDIA

Biocon-Mylan develop biosimilar to treat cancer

Rupali Mukherjee, TNN Jan 18, 2014, 04.11PM IST

http://articles.timesofindia.indiatimes.com/2014-01-18/mumbai/46324448_1_herceptin-her2-testing-breast-cancer

MUMBAI: Bangalore-based Biocon announced the launch of CANMAb, a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb, developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Roche's Herceptin.

Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer. CANMAb will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with CANMAb.

Lack of affordable treatment options has limited the extent of HER2 testing, and it is believed that the proportion of HER2-positive patients is probably higher.

Roche's Herceptin costs close to an eye-popping Rs 1 lakh for a month. CANMAb is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients in February. The injection will be available in 150 mg to 440 mg variants priced in the range of Rs 19,500 to Rs 57,500 respectively. The 440 mg variety is 25% cheaper than the competition drug.

In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

This is the first drug developed by Biocon in partnership with Mylan, the US-based generic and specialty pharma company.

Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Ltd, said: "The launch of CANMAb in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world- class product."

Biocon launches cheaper breast cancer drug

Updated: January 18, 2014 23:37 IST

<http://www.thehindu.com/business/Industry/biocon-launches-cheaper-breast-cancer-drug/article5590132.ece>

The biotechnology major will start selling 'CANMab', a 25% cheaper breast cancer drug developed jointly with US-based Mylan



Biotechnology company Biocon on Saturday launched a new and cheaper drug to treat 'metastatic' breast cancer that aggressively spreads to other parts of the body.

The company said its product, CANMab, the world's first 'biosimilar' or remake of Swiss multinational Roche's original drug trastuzumab, would cost about 25 per cent less than the original.

Roche sells the drug in India as Herceptin, which generated 2012 sales worth around Rs.130 crore. Globally, it was around \$6.4 billion.

Biocon's tumour-targeting product is slated to enter the market in the first week of February.

It will make breast cancer treatment more affordable and accessible to many Indian patients who test positive for the cancer-indicating HER2 (short for human epidermal growth factor), Chairman and Managing Director Kiran Mazumdar-Shaw told a news conference.

She said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab. [It] offers the same level of safety and efficacy as the reference product [Herceptin.]"

The local version costs Rs.19,500 for a 50 mg budget vial and around Rs.57,000 for 400 mg. The original rival comes in a single 400 mg offer and costs around Rs.75,000-80,000, according to company officials.

Patients need to take at least three intravenous drug cycles lasting around three months before any change in tumour can be noticed. In India, breast cancer is the No. 2 cancer striking women and roughly 1.5 lakh new cases

are detected each year. At least a quarter of them or nearly 40,000 test positive for the HER2 and can benefit from CANMAb.

Biocon co-developed the new product with U.S. pharma major Mylan; their 2009 partnership covers four more products and a shared market.

moneycontrol.com
INDIA'S NO.1 FINANCIAL PORTAL

Biocon to start selling breast cancer drug in India in Feb

http://www.moneycontrol.com/news/business/biocon-to-start-selling-breast-cancer-drugindiafeb_1027156.html?utm_source=ref_article

Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc

Biocon said its generic version of Roche's Herceptin breast cancer treatment would be available to patients in India from the first week of February. Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.

About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.

Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.

Global sales for Herceptin were valued at about USD 6.4 billion in 2012, including about USD 21 million in India, Biocon said.

Biocon stock price

On January 20, 2014, at 09:45 hrs Biocon was quoting at Rs 454.05, up Rs 12.55, or 2.84 percent. The 52-week high of the share was Rs 491.70 and the 52-week low was Rs 255.00.

The company's trailing 12-month (TTM) EPS was at Rs 15.02 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 30.23. The latest book value of the company is Rs 110.34 per share. At current value, the price-to-book value of the company is 4.12.

Biocon's breast cancer drug Canmab to hit markets in February

Mihir Dalal

<http://www.livemint.com/Companies/rq9NPMvOBMr4ddn8sOnm6L/Biocon-to-launch-breast-cancer-drug-in-early-Feb-at-25-disc.html>

Canmab, the brand name of the biosimilar trastuzumab, is a biological copy of Herceptin, the largest selling breast cancer drug in the world

Bangalore: Biocon Ltd said it will launch its CANMAB drug to treat breast cancer in early February at a 25% discount to rival drugs.

CANMAB, the brand name of the biosimilar trastuzumab, is a biological copy of Herceptin, the largest selling breast cancer drug in the world. Herceptin generated global sales of \$6.4 billion in 2012 and \$21 million in India.

Biocon had said in late November that the Drugs Controller General of India cleared the company's application to sell a biological copy of Herceptin, owned by the Swiss drug maker Roche Holding AG.

Biocon said that there are over 145000 new breast cancer patients in India every year, of which 25% suffer from Her 2 - positive, one of the more aggressive cancers.

CANMAB, which was developed in collaboration with US-based Mylan, will be used for treating Her 2 positive cancer.

The current cost of treatment for Her 2 positive cancer is roughly Rs75,000-80,000 for a 440 mg dose, Biocon said.

CANMAB's 440 mg dose will sell at Rs57500, Biocon said. The company will also sell a 150 mg dose priced at Rs19500 to help patients save costs and reduce wastage.

Biocon has been increasing sales of biosimilars, which are similar to generic drugs, but unlike generics biosimilars aren't exact copies of biological drugs.

The company expects biosimilars to generate 20% of its sales by 2018 from roughly 5% currently.

Biocon has been collaborating with Mylan since 2009 to develop biosimilars.

Business Standard

World's 1st biosimilar drug for breast cancer

BS Reporter | Bangalore January 18, 2014 Last Updated at 22:40 IST

http://www.business-standard.com/article/companies/biocon-launches-new-injection-to-treat-breast-cancer-114011800354_1.html

Biocon with Mylan eyes emerging markets for first joint drug

Bangalore-based bio-pharmaceutical company Biocon on Saturday launched the world's first biosimilar (developed in an organism) Trastuzumab injection for the treatment of breast cancer here. This is the first drug developed by Biocon in partnership with US-based generic drug maker Mylan. The new drug, CANMAb, will be used to treat HER2-positive advanced breast cancer.

Kiran Mazumdar-Shaw, chairperson and managing director, Biocon, said the company would also launch the injection in other emerging markets. The CANMAb injection will compete with Roche's Herceptin. Herceptin's global sales were \$6.4 billion in 2012 and Indian \$21 million.

The drug has been jointly developed out of five molecules with Mylan, since a partnership was signed in 2009. Mylan will also launch CANMAb under a different brand in India.

The injection is available in 150mg and 440mg doses at Rs 19,500 and Rs 57,500, respectively. The 440mg dose costs a fourth less than competing drugs, Mazumdar-Shaw said.

Biocon has set up a factory in Bangalore to make the new injection for itself as well as Mylan. Mylan will source its requirements from Biocon for both Indian and developed markets, a senior company official said.

Biocon entered into partnership with Mylan for joint development of a series of drugs for the treatment of various cancers in 2009. At present, four other drugs are under development, of which will begin clinical trials later this year, said Abhijit Barve, president (research and development), Biocon.

Mazumdar-Shaw said breast cancer was the most prevalent cancer among Indians and CANMAb would offer a cheaper option. About 150,000 new patients are diagnosed with breast cancer every year in India, of which nearly a fourth of the cases are HER2-positive and eligible for treatment with CANMAb. Lack of cheap treatment has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher, she said.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb, which offers the same level of safety and efficacy as the reference product. The launch of CANMAb in India is an important milestone for our biosimilars programme and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product," the Biocon chief said.

Biocon aims to capture about 15 per cent of the market for anti-breast cancer drugs in India in a year. The market is estimated at Rs 130 crore a year, set to double in 2014.

JOINT EFFORT

- CANMAb, developed jointly by Biocon & Mylan, to treat advanced breast cancer
- Competing drug Roche's Herceptin (pictured) global sales \$6.4 billion in 2012 and Indian \$21 million
- Mylan to launch CANMAb under a different brand in India
- The injection in 150mg and 440mg doses to come for Rs 19,500 and Rs 57,500, respectively

- Biocon's factory in Bangalore to make the new injection for itself as well as Mylan

Business Standard

Biocon to start selling breast cancer drug in India in February

Reuters | MUMBAI January 18, 2014 Last Updated at 15:34 IST

http://www.business-standard.com/article/reuters/biocon-to-start-selling-breast-cancer-drug-in-india-in-february-114011800374_1.html

MUMBAI (Reuters) - Biocon Ltd said its generic version of Roche's Herceptin breast cancer treatment would be available to patients in India from the first week of February.

Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc.

About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.

Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drugmaker to produce cheaper copies, known as biosimilars because they are not identical to the original drug.

Global sales for Herceptin were valued at about \$6.4 billion in 2012, including about \$21 million in India, Biocon said.

(Reporting by Aradhana Aravindan; Editing by Sonya Hepinstall)

Biocon's cheaper cancer biosimilar drug to hit market in Feb

Anil Urs

<http://www.thehindubusinessline.com/companies/biocon-launches-new-drug-for-treating-breast-cancer/article5590064.ece>

Bangalore Jan 18:



Kiran Mazumdar-Shaw, Chairperson and MD, Biocon, at the launch of CANMab in Bangalore on Saturday. — G.R.N. Somashekhar

Biotech major Biocon has launched CANMab (biosimilar Trastuzumab) for treating breast cancer in the Indian market from next month.

The company has priced the drug 25 per cent lower than the market leader Herceptin, which is sold by Roche.

CANMab has been developed jointly by Biocon and the US-based Mylan and made available in 150 mg/440 mg.

The company has priced it at Rs 19,500 per vial for 150 mg and Rs 57,500 for 440 mg.

“Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMab will offer a high quality, more affordable option to breast cancer patients in India,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, after launching the drug.

“Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMab, which offers the same level of safety and efficacy as the reference product (Herceptin),” she added. Talking about the opportunity for biosimilar Trastuzumab, Kiran Mazumdar-Shaw, said: “The global sales for Herceptin stood at over \$6.4 billion in 2012, while in India it recorded sales of over \$21 million.”

“The Biocon-Mylan joint development programmes are on target.

“The two companies are working on eight molecules at present in the auto-immune and oncology space.

"Few molecules are in global clinical development, which is under way at multiple sites across the globe," said Abhijit Barve, President R&D, Biocon.

The company's branded formulations business CAGR is 30 per cent.

Business Line

Cheap drug to boost for Biocon

K.S. Badri Narayanan

http://www.thehindubusinessline.com/markets/stock-markets/cheap-drug-to-boost-for-biocon/article5594026.ece?ref=wl_markets

Shares of Biocon will hog the limelight this week as the company launched a new and cheaper drug to treat 'metastatic' breast cancer that aggressively spreads to other parts of the body.

The company said its product would cost about 25 per cent less than the original.

Roche sells the drug in India as Herceptin, which generated 2012 sales worth around Rs 130 crore. Globally, it was around \$6.4 billion. Biocon's tumour-targeting product is slated to enter the market in the first week of February. It will make breast cancer treatment more affordable and accessible to many Indian patients who test positive for the cancer-indicating HER2 (short for human epidermal growth factor), Chairman and Managing Director Kiran Mazumdar-Shaw told a news conference.

FIRSTPOST. BUSINESS

Biocon launches world's first biosimilar drug for breast cancer

Jan 19, 2014

<http://www.firstpost.com/business/biocon-launches-worlds-first-biosimilar-drug-for-breast-cancer-1347543.html>

Biotechnology company Biocon on Saturday launched a new and cheaper drug to treat 'metastatic' breast cancer that aggressively spreads to other parts of the body. Biocon which developed the drug in association with US drugmaker Mylan received the approval for CANMAb, the biosimilar version of anti-cancer drug Herceptin, last year.

The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount.

CANMAb will be available at about 25 percent discount to the current list price of the reference product - Roche's Herceptin - in India, which is already significantly lower than its price in developed markets, it added.

Herceptin 440mg, is currently sold at Rs 75,000 rpt 75,000 in the country. Biocon's product would be available in 150 mg and 440 mg strengths which costs Rs 57,500. "In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement," the company said.

The company would start selling the drug to patients around the first week of February 2014, it added. Around 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25 per cent cases are eligible for treatment with CANMAb.

Commenting on the launch, Biocon Ltd CMD Kiran Mazumdar Shaw said: "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product."

CANMAb, which has been developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Roche's Herceptin drug.

"Both 150 and 440 mg formulations of CANMAb can be stored for one month which is an important offering for patients in India, as it will ensure that there is no under-dosing or wastage of drug which is quite common today," the company said.

The global sales for Herceptin stood at \$6.4 billion in 2012, while in India it recorded sales of \$21 million.



Biocon to start selling breast cancer drug in India in February

<http://in.reuters.com/article/2014/01/18/biocon-cancer-idINDEEA0H03O20140118>

(Reuters) - Biocon Ltd(BION.NS) said its generic version of Roche's(ROG.VX) Herceptin breast cancer treatment would be available to patients in India from the first week of February.

Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc.

About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.

Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drugmaker to produce cheaper copies, known as biosimilars because they are not identical to the original drug.

Global sales for Herceptin were valued at about \$6.4 billion in 2012, including about \$21 million in India, Biocon said.



Biocon introduces CANMAb for treating breast cancer in India

IRIS (18-JAN-14)

<http://www.myiris.com/newsCentre/storyShow.php?fileR=20140118143844043&dir=2014/01/18>

Biocon, Asia's premier biotechnology company, today introduced CANMAb (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb, developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients in India. Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly

25% cases are HER2-positive and eligible for treatment with CANMAb. Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher.

Kiran Mazumdar-Shaw, chairperson & managing director, Biocon, said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product. The launch of CANMAb in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product."

CANMAb is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient's condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of CANMAb can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.

CANMAb is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients around the first week of February 2014. CANMAb will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

The global sales for Herceptin stood at USD 6.4 billion in 2012, while in India it recorded sales of USD 21 million.

Shares of the company declined 4.72% to settle at Rs 441.50 on Friday.



Biocon's New Breast Cancer Drug CANMAb to Hit Markets Next Month

Economic Bureau - BNAGALORE

<http://www.newindianexpress.com/business/news/Biocons-New-Breast-Cancer-Drug-CANMAb-to-Hit-Markets-Next-Month/2014/01/20/article2008724.ece>

Biocon has announced a new drug for the treatment of HER2 positive metastatic breast cancer in the country. A biosimilar trastuzumab, CANMAb, developed jointly by Biocon and Mylan, will be the world's first biosimilar version of Herceptin and will be available in dosages of 150 mg/440 mg from February.

Global sales for Herceptin stood at \$6.4 billion in 2012 while in India sales were at \$21 million. The drug will be manufactured at Biocon facilities in Bangalore and its price will be around 25% lesser than the current list price of the reference product in India, Biocon said.

The 150 mg formulation will be priced at Rs 19,500 per vial of medicine.

Kiran Mazumdar-Shaw, MD, Biocon said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb, which offers the same level of safety and efficacy as the reference product." Approximately 1.5 lakh new patients are diagnosed with breast cancer every year out of which 25%, according to Biocon, are HER2 positive.

It acts by interfering with HER2 protein production and stops the growth of cancer cells. It can be administered intravenously once every 3 weeks or on a weekly basis. Both versions of the drug can be stored for 1 month which will reduce underdosing or wastage.

Biocon Launches a Biosimilar Trastuzumab for Treating Breast Cancer in India

http://www.equitybulls.com/admin/news2006/news_det.asp?id=132636

Biocon Ltd has introduced CANMAb(TM) (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb(TM), developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients in India.

Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb(TM) will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with CANMAb(TM). Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher.

Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon Ltd, said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb(TM) (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product. The launch of CANMAb(TM) in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product."

CANMAb(TM) is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient's condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of CANMAb(TM) can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.

CANMAb(TM) is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients around the first week of February 2014. CANMAb(TM) will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

Developing a quality biosimilar monoclonal antibody requires high technical skills, significant investments in clinical development and manufacturing and long gestation periods resulting in significantly higher costs of development and manufacturing compared to common chemistry-based pharmaceutical drugs.

India is witnessing increased usage of targeted therapies like biologics as compared to cytotoxics. This trend is likely to continue given the improved treatment outcomes.

The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like CANMAb(TM) will make access more affordable and thereby expand the patient pool.

The global sales for Herceptin stood at US\$ 6.4 bn in 2012, while in India it recorded sales of US\$21 Mn.

Shares of Biocon Ltd was last trading in BSE at Rs.441.50, down by Rs.21.85 or 4.72%. The stock hit an intraday high of Rs.465.40 and intraday low of Rs.439.

The total traded quantity was 1.17 lakh shares as compared to 2 week average of 1.22 lakh shares.

Biocon's cancer drug not affordable: Activists

<http://www.deccanherald.com/content/381538/biocon039s-cancer-drug-not-affordable.html>

New Delhi, Jan 19, 2014 DHNS:

Indian biotechnology major Biocon's new breast cancer medicine "CANMAb" is scarcely a cause for cheer as it is as costly as the original molecule "Herceptin" made by a multinational pharmaceutical company, say activists campaigning for cheaper anti-cancer medicines.

A 440 mg vial of CANMAb (medical name "trastuzumab") costs about Rs 56,000, while a similar medicine of the same dose from drug major Roche would cost about Rs 75,000 in India.

Many Roche dealers already offer discounts to "steady customers", the patients needing long-term treatment. As a result, the street price of Herceptin ranges from Rs 55,000 to Rs 57,000 for a vial of 440 mg. "Biocon's price for the bio-similar is not significantly lower than what is available from Roche," said Leena Menghaney from the Campaign for Affordable Trastuzumab.

CANMAb is the biosimilar version of the original medicine, developed by Roche, to treat a common type of breast cancer in which patients carry HER2 gene.

Breast cancer remains the commonest cause of cancer among women. Approximately 1.5 lakh new Indian patients are diagnosed with breast cancer every year of which nearly 25 per cent carry HER2 gene, making them eligible for treatment with the new medicine.

CANMAb is the world's first biosimilar version of Herceptin, which is the only medicine to treat HER2 positive cases.

Market tactic

The Bangalore-based company, however, has launched a 150 mg dose of the medicine, priced at Rs 19,500 per vial. "Many a times, doctors prescribe the 440 mg dose because lower dosage is not available in the market. That's where our product will have an edge," said a spokesperson of Biocon.

"Also, on both dosages, we offer 25 per cent discount, which will make the drug even more affordable," she told Deccan Herald.

Unlike the product currently available in the market, both 150 and 440 mg formulations of CANMAb can be stored for a month to prevent wastage of drug which is quite common, said the spokesperson.

The activists, however, have a different take and want the medicine within a price band of Rs 5,000. "The introduction of the bio-similar will make little or no difference to women whose income is less than Rs 30,000 per month." said another activist Kalyani Menon Sen.

Biocon introduces CANMAb for treating breast cancer in India

<http://pharma.financialexpress.com/latest-updates/3248-biocon-introduces-canmab-for-treating-breast-cancer-in-india?SocialMedia>

CANMAb, developed jointly by Biocon and Mylan under a global partnership

Biocon, introduced CANMAb (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb, developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients in India.

Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25 per cent cases are HER2-positive and eligible for treatment with CANMAb. Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher.

Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product. The launch of CANMAb in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world- class product."

CANMAb is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every three weeks or on a weekly basis depending on the patient's condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of CANMAb can be stored for one month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.

CANMAb is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients around the first week of February 2014. CANMAb will be available at about 25 per cent discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

Developing a quality biosimilar monoclonal antibody requires high technical skills, significant investments in clinical development and manufacturing and long gestation periods resulting in significantly higher costs of development and manufacturing compared to common chemistry-based pharmaceutical drugs. India is witnessing increased usage of targeted therapies like biologics as compared to cytotoxics. This trend is likely to continue given the improved treatment outcomes.

The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like CANMAb will make access more affordable and thereby expand the patient pool.



Biocon to start selling breast cancer treatment drug in India in February

Reuters | Updated On: January 18, 2014 17:00 (IST)

<http://profit.ndtv.com/news/corporates/article-biocon-to-start-selling-breast-cancer-treatment-drug-in-india-in-february-378033>

Mumbai: Biocon Ltd said its generic version of Roche's Herceptin breast cancer treatment drug would be available to patients in India from the first week of February.

Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.

About 150,000 people are diagnosed with breast cancer every year in India, of which 25 per cent are eligible for treatment with trastuzumab, Biocon said.

Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drug makers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.

Global sales for Herceptin were valued at about \$6.4 billion in 2012, including about \$21 million in India, Biocon said.

NetIndian

Biocon introduces biosimilar for treating breast cancer in India

<http://netindian.in/news/2014/01/19/00027625/biocon-introduces-biosimilar-treating-breast-cancer-india>

Biotechnology major Biocon Limited has introduced CANMAb (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India.

CANMAb, developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients in India, a press release from the company said.

The release said breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb would offer a high quality, more affordable option to breast cancer patients in the country

It said that, approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with CANMAb.

Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher, the release said.

"Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product," Ms Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Ltd, said.

"The launch of CANMAb in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world-class product," she said.

According to the release, CANMAb is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells.

"It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient's condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of CANMAb can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today," it said.

CANMAb is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients around the first week of February 2014.

The release said CANMAb will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

The company said developing a quality biosimilar monoclonal antibody requires high technical skills, significant investments in clinical development and manufacturing and long gestation periods resulting in significantly higher costs of development and manufacturing compared to common chemistry-based pharmaceutical drugs.

"India is witnessing increased usage of targeted therapies like biologics as compared to cytotoxics. This trend is likely to continue given the improved treatment outcomes.

"The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like CANMAb will make access more affordable and thereby expand the patient pool," it said.

The global sales for Herceptin stood at ~US\$ 6.4 billion in 2012, while in India it recorded sales of ~US\$21 million.



Biocon's affordable breast cancer drug CANMAb launched

Editorial Team January 20, 2014 at 9:50 am

<http://health.india.com/news/biocons-affordable-breast-cancer-drug-canmab-launched/>

India's leading biotechnology firm Biocon Ltd. has released a new drug to treat metastatic breast cancer it developed jointly with US-based pharma major Mylan.

Claimed to be the world's first bio-similar version of Herceptin, a monoclonal antibody used to treat certain breast cancers, the Biocon drug (CANMAb) offers an affordable option to patients in India.

'Breast cancer is the most prevalent malignancy among Indian women ahead of cervical cancer, as nearly 1.5 lakh new patients are diagnosed with it every year across the country,' the company said in a statement here Sunday.

As a targeted therapy for treatment, the drug acts by interfering with Her2 (genes) protein production and stopping growth of cancer cells.

Though given intravenously once a week or in three weeks depending on the patient's condition, the drug can be stored for one month.

'We want to make a difference in treating Her2-positive breast cancer by giving access to affordable treatment with the drug, which offers same safety and efficacy as its reference product (Herceptin),' Biocon chairperson Kiran Mazumdar Shaw said in the statement.

Produced in the company's biologics facility here, the drug will be available in the market from early February at 25 percent cheaper than the reference product, sold at Rs.19,500 per vial, though lower than in developed markets. (Read: New breast cancer treatment in the offing?)

'Developing a biosimilar monoclonal antibody requires skills, huge investment in clinical development, manufacturing and gestation period, leading to higher costs than common chemistry-based drugs,' Shaw said.

With increased usage of targeted therapies like biologics as against cytotoxics, a drug used to directly kill tumour cells, the new trend is set to continue in view of the improved treatment outcomes.

Global sale of Herceptin was \$6.4 billion in 2012, including \$21 million in India. (Read: Breast cancer: Top 10 myths busted)

As a leading oncology firm, Biocon has in the past delivered a novel biologic drug for head and neck cancer, benefitting about 5,500 patients across the country.

'Though standard treatment for breast cancer is surgery, chemotherapy, hormone therapy and targeted therapies, survival rate in the US has improved to about 90 percent after biologics was introduced with improved screening and other treatment enhancements,' the statement added. (Read: 10 tips to cope with breast cancer)

What is Breast Cancer?

Breast cancer is a major problem in India. According to Dr Sumeet Shah, 'Breast cancer is the most common cancer in Indian cities, accounting for a staggering 25 to 35 percent of all cancers in women in cities! Even in rural areas, the incidence is steadily rising. In the year 2008, almost 1,15,000 new cases of breast cancer were reported in India, and about 53,000 death due to breast cancer were recorded.' Certainly more awareness is needed and many campaigns have taken place over the last few years. In this mega guide, we'll tell you everything you need to know about the disease.

Causes

Unhealthy style, stress, imbalanced food, irregular sleeping hours, etc. are some of the things that can lead to breast cancer.

Other reasons include:

- Early menarche (start of menstruation) and late menopause which exposes the body's cells to more than normal oestrogen. While oestrogen is an important and protective hormone, it has a proliferative effect on cells of the breast and uterus which results in cancer.
- First delivery beyond 30 years of age increase chances of developing breast cancer
- Genetic predisposition – about 6-8% of breast and ovarian cancers seem to be family-based. The genetic changes are passed down the generation, which will increase their chance of developing cancer. (Read: Breast cancer — causes, symptoms, myths, diagnosis, treatment)



Biocon releases drug to treat breast cancer

Sunday, Jan 19, 2014, 17:43 IST | Agency: IANS

<http://www.dnaindia.com/health/report-biocon-releases-drug-to-treat-breast-cancer-1953697>

India's leading biotechnology firm Biocon Ltd. has released a new drug to treat metastatic breast cancer it developed jointly with US-based pharma major Mylan.

Claimed to be the world's first bio-similar version of Herceptin, a monoclonal antibody used to treat certain breast cancers, the Biocon drug (CANMAb) offers an affordable option to patients in India.

"Breast cancer is the most prevalent malignancy among Indian women ahead of cervical cancer, as nearly 1.5 lakh new patients are diagnosed with it every year across the country," the company said in a statement here Sunday.

As a targeted therapy for treatment, the drug acts by interfering with Her2 (genes) protein production and stopping growth of cancer cells.

Though given intravenously once a week or in three weeks depending on the patient's condition, the drug can be stored for one month.

"We want to make a difference in treating Her2-positive breast cancer by giving access to affordable treatment with the drug, which offers same safety and efficacy as its reference product (Herceptin)," Biocon chairperson Kiran Mazumdar Shaw said in the statement.

Produced in the company's biologics facility here, the drug will be available in the market from early February at 25 percent cheaper than the reference product, sold at Rs.19,500 per vial, though lower than in developed markets.

"Developing a biosimilar monoclonal antibody requires skills, huge investment in clinical development, manufacturing and gestation period, leading to higher costs than common chemistry-based drugs," Shaw said.

With increased usage of targeted therapies like biologics as against cytotoxics, a drug used to directly kill tumour cells, the new trend is set to continue in view of the improved treatment outcomes.

Global sale of Herceptin was \$6.4 billion in 2012, including \$21 million in India.

As a leading oncology firm, Biocon has in the past delivered a novel biologic drug for head and neck cancer, benefitting about 5,500 patients across the country.

"Though standard treatment for breast cancer is surgery, chemotherapy, hormone therapy and targeted therapies, survival rate in the US has improved to about 90 percent after biologics was introduced with improved screening and other treatment enhancements," the statement added.



"CANMAb™" - World's First Biosimilar Trastuzumab for Treating Breast Cancer Launched By Biocon in India

<http://www.biotecnika.tv/press-conference-of-dr-kiran-mazumdar-shaw-cmd-biocon-launching-canmab/>

Biocon Ltd, Asia's leading biotechnology company, launched today CANMAb™ (150 mg/440 mg), a biosimilar trastuzumab aimed for the treatment of HER2-positive metastatic breast cancer in India. CANMAb™, is the world's first biosimilar version of Herceptin, developed jointly by Biocon and Mylan under a global partnership. It has been introduced to aid cancer patients in India.

Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Ltd, said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb™ (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product. The launch of CANMAb™ in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world- class product."

Breast cancer is the most rampant and ubiquitous cancer among Indian women's, surpassing cervical cancer and here CANMAb™ will play an important part offering a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with CANMAb™. Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher.

CANMAb™ is a targeted therapy for the treatment of HER2-positive breast cancer . Its mode of action includes interference with HER2 protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient's condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of CANMAb™ can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.

Biocon's biologics facility in Bangalore is manufacturing CANMAb™ and will be available to patients around the first week of February 2014. 25% discount will be provided on the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.



Biocon introduces CANMAb for patients in India

<http://www.apnnews.com/2014/01/18/biocon-introduces-canmab-for-patients-in-india/>

Bangalore : Biocon Ltd, Asia's premier biotechnology company, today introduced CANMAb™ (150 mg/ 440 mg), a biosimilar Biocon Biocon introduces CANMAb for patients in Indiastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb™, developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients in India.

Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb™ will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with CANMAb™. Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher.

Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Ltd, said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb™ (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product. The launch of CANMAb™ in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world- class product."

CANMAb is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient's condition. Unlike the product currently

available in the market, both 150 and 440 mg formulations of CANMAb™ can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.

CANMAb is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients around the first week of February 2014. CANMAb will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

Developing a quality biosimilar monoclonal antibody requires high technical skills, significant investments in clinical development and manufacturing and long gestation periods resulting in significantly higher costs of development and manufacturing compared to common chemistry-based pharmaceutical drugs.

India is witnessing increased usage of targeted therapies like biologics as compared to cytotoxics. This trend is likely to continue given the improved treatment outcomes.

The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like CANMAb™ will make access more affordable and thereby expand the patient pool.



Biocon launches world's first Biosimilar 'CANMAb' in India

<http://www.biospectrumindia.com/biospecindia/news/206917/biocon-launches-world-s-biosimilar-canmab-india/page/1>

Biocon's CMD Dr Kiran Mazumdar-Shaw today in Bangalore officially launched CANMAb – the world's first biosimilar trastuzumab for treating HER2-positive metastatic breast cancer.

CANMAb has been jointly developed by Biocon in partnership with Mylan and it is said to be the world's first biosimilar version of Herceptin.

At the launch this morning, Dr Kiran said, "We are announcing the launch of a very important product that we have developed over the years. We have branded this product as CANMAb, which is all about Convenience, Affordability and something New from India."

After 7 years of painstaking research and development, CANMAb is exclusively manufactured at Biocon's biologics facility in Bangalore and will be available for patients during the first week of February 2014.

CANMAb will be available in 150mg and 450mg quantities, priced at Rs 19,500 and Rs 57,500 per vial respectively, compared to Herceptin, which costs Rs 75,000 for 440mg.

Breast cancer is the most common cancer among women across India and the world. The incidence of breast cancer in the world is roughly about 1.6 million cases reported each year.

About 1.4 lakh cases of breast cancer are reported in India annually and 25% of them are HER2-positive. HER2-positive is said to be aggressive and fast-growing breast cancer, which has much higher risk of early recurrence and death. The launch saw the presence of Biocon's key management team including, Dr Arun Chandavarkar, COO; Mr Shukrit Sudhir Chimote, India head & VP, branded formulations; and Dr Abhijit Barve, president, R&D. Dr Kiran revealed that more than 80% of the deaths due to non-communicable diseases (NCD's) occur in the developing countries and cancer is one among them. "Most drug innovation takes place in the developed world. What is also important is that only 1 out of every 4 new molecular entities is made available in the developing markets. This is a major challenge that we face," she added. Dr Kiran spoke about the affordability challenge that is being faced in the

developing economy. She said that unlike the developing world, the developed world has a very good coverage of health requirements through national health care systems.

"Even though drugs are made available to the developing economies, it is still beyond the reach of many patients in the developing economies," opined Dr Kiran. According to Dr Kiran, 45% of the families with one cancer patient face catastrophic expenditure in India. About 25% of the families with one cancer patient are pushed below the poverty line. The cost of treatment for metastatic breast cancer patient in India is about Rs 20,000-30,000 per month, and it is Rs 80,000 per month for treating HER2-positive using innovator trastuzumab. In her presentation, Dr Kiran pointed out that in Europe, a patient has to spend just about 0.5 days of his wages for the purpose of OAD treatment course, compared to south-east Asians who need to spend 1.3 days of their wages and African's up to 8.4 days of their wages. She also presented that, in Europe a patient has to spend approximately 143 days of his or her wages to purchase a cancer metastatic treatment course; 372 days wages in south-east Asia; 1285 days wages in Latin & South America; and 2398 days' worth wages in Africa.

"A lot of middle income countries face the 5/80 cancer disequilibrium. 95% of the global spending on cancer drugs is in high-income countries. Only about 5% is spent in developing economy and yet the burden of diseases is only in the developing economy. In south-east Asia, the per capita income is roughly about \$3000 and the treatment for leukemia is about \$20,000. Here we can see how skewed this whole cancer treatment regime is," added Dr Kiran. In 2010, there were about under a million cancer cases reported in India. But this may rise to 1.2 million by 2020. Today, India stands next to US and China in this regard. In the past, cancer was treated through radiation and chemotherapies, but now it is more of using targeted therapies like biologics. "Biologics are very expensive drugs to be developed. They are complex, and in the US, biologics cost anywhere between \$100,000-500,000 per year. This is absolutely unaffordable in a country like India. This made us believe to develop a drug in terms of biosimilar," explained Dr Kiran. To develop a biosimilar, it take about 50 times the cost and 4 times the time in comparison to developing small molecule generics. In her concluding remarks, Dr Kiran Mazumdar expressed, "We have now developed this important biosimilar. We hope to take this drug to patients who need it. We focus on making it very accessible to patients beyond just providing drugs at lower cost. We will have a special program for compassionate use at discounted schemes for the poor. We hope it will really impact patients suffering from HER-2 positive breast cancer."

The clinical trials (CANMAb Vs Herceptin) were carried in 23 centers across India for a duration of 24 weeks. Dr Arun Chandavarkar added, "We started working on this drug before partnering with Mylan back in 2007/08. It took us a lot more time and money, and a significant investment to bring this biologic product to the market simply because it is a complex molecule that is difficult to develop, requiring elaborate clinical trials unlike small molecule generics." So far, Biocon and Mylan has co-developed 8 molecules in partnership.



Biocon launches first biosimilar version of Roche's breast cancer drug Herceptin

http://www.firstwordpharma.com/node/1180229?tsid=28®ion_id=6#axzz2qqwU8pQ8

Anna Bratulic

Biocon announced that it has introduced the "world's first" biosimilar version of Roche's Herceptin (trastuzumab) for the treatment of HER2-positive metastatic breast cancer. The company said CANMAb, which was jointly developed under a 2009 partnership with Mylan, will be available in the Indian market as of "around the first week of February" and has been priced at about a 25-percent discount to the cost of Herceptin in that country.

Kiran Mazumdar-Shaw, Biocon's chairperson and managing director, said the drugmaker "intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb, which offers the same level of safety and efficacy as the reference product." She added that the company also plans to launch the injectable drug in other emerging markets.

Biocon noted that 25 percent of the roughly 150 000 people diagnosed with breast cancer every year in India are eligible for treatment with CANMAb, which the Drugs Controller General of India cleared for use in November last year. Under the 2009 collaboration, Mylan holds exclusive commercialisation rights to biosimilar Herceptin in the US, Canada, Japan, Australia, New Zealand and in the EU and European Free Trade Association countries, while the drugmakers hold co-exclusive commercialisation rights in India. Mylan will market the biosimilar product under the name Hertraz.

In August 2013, Roche said it would not seek to recover its Indian patent for Herceptin, and that its decision not to pursue the patent application wouldn't affect the drug's availability in the country. The Indian government had previously said that the Herceptin patent lapsed after the company failed to comply with local regulations following a post-grant challenge on the breast cancer drug. For related analysis on India's approval of biosimilar Herceptin, see ViewPoints: Biosimilar Herceptin approved in India, but regulatory requirements somewhat below bar set by Europe.

Roche entered into an alliance with Emcure Pharmaceuticals in 2012 for the local manufacturing and marketing of the Swiss drugmaker's innovative molecules in India, including Herceptin. According to Biocon, Herceptin recorded global sales of \$6.4 billion in 2012, including \$21 million in India.



Biocon akan Jual Obat Kanker Payudara di India

<http://www.bisnis-jabar.com/index.php/berita/biocon-akan-jual-obat-kanker-payudara-di-india>

Bisnis-jabar.com, BANDUNG – Biocon Ltd mengatakan akan mengeluarkan obat versi generik dari Roche Herceptin untuk kanker payudara. Obat ini akan tersedia bagi para pasien di India pada minggu pertama Februari 2014.

Biocon yang berbasis di Bangalore mengembangkan trastuzumab biosimilar, yang juga menerima persetujuan pemasaran obat regulator di India pada bulan November tahun lalu, dengan basis Mylan Inc.

“Sekitar 150.000 orang didiagnosis kanker payudara setiap tahunnya di India. Di mana hanya 25% yang memenuhi syarat untuk pengobatan dengan trastuzumab,” jelas Biocon.

Roche memutuskan untuk tidak mengejar hak paten obat Herceptin (trastuzumab) yang diakui sebagai obat kanker payudara di India ini. Dia justru membuka jalan bagi produsen obat generik untuk menghasilkan salinan obat yang lebih murah, yang dikenal sebagai biosimilars.

Biocon mengatakan penjualan global untuk Herceptin ini senilai sekitar US\$6,4 miliar pada 2012, dan sekitar US\$21 juta di India. (reuters/m02)

Biocon introduces CANMAb biosimilar for treating Breast Cancer

<http://news.webindia123.com/news/Articles/India/20140118/2323365.html>

Pharma major Biocon Ltd today introduced CANMAb (150 mg/440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer, in India.

CANMAb is the first indigenously produced biologic, developed jointly by Biocon and Mylan under a global partnership. It is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients in India.

Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb will offer a high quality, more affordable option to breast cancer patients in India.

Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25 per cent cases are HER2-positive and eligible for treatment with CANMAb.

Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher.

While 150 mg injection costs Rs 19,500 per vial, the 450 mg injection costs Rs 57,500. This is 20 per cent cheaper compared to imported Herceptin, which comes at Rs 75,000 for 440 mg veil. Herceptin is the reference product of CANMAb. MORE UNI RS GM PG1520 NNNN



Biocon Introduces CANMAb™ - World's First Biosimilar Trastuzumab for Treating Breast Cancer in India

<http://www.moneylife.in/business-wire-news/biocon-introduces-canmabtm---worlds-first-biosimilar-trastuzumab-for-treating-breast-cancer-in-india/37978.html>

Biocon Ltd, Asia's premier biotechnology company, today introduced CANMAb™ (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb™, developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients in India.

Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb™ will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with CANMAb™. Lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is probably higher.

Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Ltd, said, "Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb™ (biosimilar trastuzumab), which offers the same level of safety and efficacy as the reference product. The launch of CANMAb™ in India is an important milestone for our biosimilars program and

demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world- class product.”

CANMAb™ is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with HER2 protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient’s condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of CANMAb™ can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.

CANMAb™ is being manufactured at Biocon’s biologics facility in Bangalore and will be available to patients around the first week of February 2014. CANMAb™ will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb’s 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

Developing a quality biosimilar monoclonal antibody requires high technical skills, significant investments in clinical development and manufacturing and long gestation periods resulting in significantly higher costs of development and manufacturing compared to common chemistry-based pharmaceutical drugs.

India is witnessing increased usage of targeted therapies like biologics as compared to cytotoxics. This trend is likely to continue given the improved treatment outcomes.

The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like CANMAb™ will make access more affordable and thereby expand the patient pool.

The global sales for Herceptin stood at ~US\$ 6.4 bn in 2012, while in India it recorded sales of ~US\$21 Mn.

Biocon: A Leading Oncology Company

Biocon today is recognised as one of the leading oncology companies in the country. It has delivered a novel biologic BioMAb EGFRTM for head & neck cancer in India.

Till date, over 5,500 patients have benefitted from this novel product.

Notes to the Editor:

CANMAb™ Development

CANMAb™ (biosimilar trastuzumab) is being made available to cancer patients following a multi-centric clinical trial in India to demonstrate comparability and similarity in PK (pharmacokinetics), safety, efficacy and immunogenicity with the reference product. This trial followed international regulatory and quality guidelines to ensure the data generated are of high quality and reliability. Extensive physico-chemical and biological characterization data has been generated using multiple high end techniques for demonstrating biosimilarity of CANMAb™ at a molecular level.

The Biocon-Mylan joint development program also includes additional global clinical development, which is underway at multiple sites across the globe.

Biologics improve survival rate

Standard treatments for breast cancer include surgery, chemotherapy, hormone therapy and targeted therapies, including biologics. The survival rate for breast cancer patients in the US has improved to nearly 90% after the introduction of biologics, improved screening, and other treatment enhancements.

#Herceptin is a registered brand of Roche

बायोकाॅन ने लॉन्च की ब्रेस्ट कैंसर की सस्ती दवा

नई दिल्ली

<http://navbharattimes.indiatimes.com/business/business-news/biocons-breast-cancer-drug-canmab-to-hit-markets-next-month/businessarticleshow/29070780.cms>

जानी-मानी बायोटेक्नोलॉजी कंपनी बायोकाॅन ने कहा है कि वह भारत में अगले महीने से एंटी-ब्रेस्ट कैंसर ड्रग कैनमैब बेचना शुरू करेगी। यह स्विट्जरलैंड की कंपनी रोश की दवा हरसेप्टिन का बायोसिमिलर वर्जन है।

बायोकाॅन ने यह दवा अमेरिका की मायलन के साथ मिलकर तैयार की थी। उसे पिछले साल भारतीय ड्रग रेगुलेटर की मंजूरी मिली थी। बायोकाॅन की दवा की एक वायल 19,500 रुपये की होगी। हरसेप्टिन का दाम 75,000 रुपये है। बायोकाॅन की सीएमडी किरण मजूमदार शॉ ने एक स्टेटमेंट में कहा कि भारत में कैनमैब की लॉन्चिंग हमारे बायोसिमिलर प्रोग्राम के लिए मील का पत्थर है और इससे हाई-क्वालिटी वर्ल्ड क्लास प्रॉडक्ट को अफोर्डेबल प्राइस में पेश करने की हमारी क्षमता का पता भी चलता है।

बयान में कहा गया कि यह दवा भारत में इसे रेफरेंस प्रॉडक्ट की मौजूदा लिस्ट प्राइस से काफी डिस्काउंट पर उपलब्ध होगी। बायोकाॅन ने कहा कि यह दवा कंपनी के बंगलुरु वाले कारखाने में तैयार की जाएगी। उसने कहा कि दवा फरवरी के पहले सप्ताह में मरीजों को मिलने लगेगी।

माना जाता है कि रोश की हरसेप्टिन एचईआर 2 कैंसर सेल को टारगेट करने के मामले में सबसे ज्यादा प्रभावी है। एचईआर 2 सेल के कारण ही ब्रेस्ट कैंसर होता है। पिछले साल अगस्त में रोश ने भारत में हरसेप्टिन का पेटेंट आगे नहीं बढ़ाने का फैसला किया था। इसके चलते दूसरी जेनेरिक ड्रग मेकर्स के लिए इसे तैयार करने का रास्ता साफ हो गया था। इस दवा को तैयार करने की प्रक्रिया काफी जटिल है, लिहाजा बायोकाॅन और रोश को छोड़कर कोई और कंपनी इसे नहीं बनाती है। रोश भी इसे भारत में तैयार करती है। हालांकि, मुंबई की बीडीआर फार्मा भी अब हरसेप्टिन के जेनेरिक वर्जन के लिए शोध कार्य कर रही है।